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Abstract 
This thesis collects doctoral studies about developmental trajectories of autism in preschooler 
age and clinical and neurobiological indices of the different outcomes observed. The work has 
been organized into five parts. In particular, the first report regards a review study on the 
new diagnostic classification of Autism Spectrum Disorders (hereinafter referred to as ASD) in 
DSM-5. The second work is a collection of doctoral studies about diagnostic stability of ASD 
between 3 and 5 years of age. According to this study, Autistic Disorder (herein after referred 
to as AD) diagnosis is more stable than Pervasive Developmental Disorder Not Otherwise 
Specified (hereinafter referred to as PDD-NOS); the amount and type of treatment are not 
strictly related to the outcome; upon their first evaluation at about 3 y.o., ADOS Calibrated 
Severity Score (CSS), but not non verbal IQ (nvIQ), may be hypothesized to be a predictive 
factor of the outcome in ASD children.  
The third study has been carried out with the collaboration of The Italian Autism Network 
(ITAN) study, a large national multi-centric project initiated by SmithKline Foundation with 
the aim of collecting biological materials (DNA, RNA, plasma and lymphoblastoid cell lines) 
and clinical and functional data from ASD probands in order to test whether some genetic 
markers already scrutinized in Autism Studies are actually associated with ADSs in a newly 
collected Italian ASD cohort.  
A significant association was found for two of seven markers: rs4307059 T allele and rs35678 
TC genotype located at loci previously associated with social and verbal communication skills. 
The fourth study has been carried out in collaboration with Prof. Persico’s research group 
(Child and Adolescent Neuro Psychiatry Unit at the University "Campus Bio-Medico" of 
Rome). It is a multi-centric study in which urinary levels of p-cresol have been found to be 
significantly higher in 59 non-syndromic autistic children than in 59 tightly age- and sex-
 x 
matched controls. Moreover, p-cresol levels have been found to be significantly higher in 
female autistic children if compared to males, in more severely affected autistic children 
regardless of their sex, and in children who experienced regressive onset. 
In the fifth and last work we have studied 36 autistic subjects of whom we have collected data 
on developmental clinical profiles and urinary samples, thus analyzing the concentrations of 
total urinary p-cresol. The aims of this study are not only to confirm an elevation of this toxic 
compound in ASD children, but also to check for correlations between  p-cresol levels on the 
one hand, and the clinical phenotypes and developmental profiles on the other hand.  
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Riassunto 
 
Questa tesi raccoglie gli studi effettuati nel corso del dottorato riguardanti le traiettorie di 
sviluppo dell’autismo nell’età prescolare e gli indici clinici e neuro-biologici dei diversi profili 
di outcome osservati. Il lavoro è stato organizzato in 5 parti. In particolare, il primo resoconto 
è la sintesi di un lavoro di review sulla nuova proposta di classificazione dei Disturbi dello 
Spettro Autistico nel DSM-5. Il secondo resoconto raccoglie una serie di studi effettuati nel 
corso del dottorato sulla stabilità diagnostica dei Disturbi dello Spettro Autistico (DSA) tra i 3 
e i 5 anni di età. Complessivamente, abbiamo riscontrato una più alta stabilità diagnostica del 
Disturbo Autistico rispetto al DPS NAS; abbiamo riscontrato che la quantità e il tipo di 
trattamento non sono strettamente correlati all’outcome e che il CSS (ADOS Calibrated 
Severity Score), ma non il QI non verbale, alla valutazione basale effettuata a 3 anni può essere 
considerato come fattore predittivo dell’outcome nei bambini con ASD.  
Il terzo studio nasce dalla collaborazione con lo studio Italian Autism Network (ITAN) (un 
grande progetto multi-centrico nazionale) avviato dalla Fondazione Smith Kline con lo scopo 
di raccogliere materiali biologici (DNA, RNA, plasma and linee cellulari linfoblastoidi) e dati 
clinico-funzionali da probandi con DSA al fine di testare se alcuni markers genetici ben 
studiati fossero associati all’autismo in una nuova coorte di DSA italiani. Una associazione 
significativa è stata evidenziata per 2 dei 7 markers studiati: l’allele T di rs4307059 e il 
genotipo TC di rs35678 posti in loci già precedentemente associati  alle competenze sociali e 
comunicative.  
La quarta ricerca è stata realizzata in collaborazione con il Prof. Persico e l’unità di 
Neuropsichiatria dell’Infanzia e dell’Adolescenza dell’Università Campus Bio-Medico di Roma. 
Si tratta di uno studio multi-centrico nell’ambito del quale i livelli urinari di p-cresolo sono 
stati riscontrati significativamente più alti in 59 bambini autistici non sindromici  rispetto a 
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59 controlli strettamente appaiati per età e sesso. Inoltre, i livelli di p-cresolo erano 
significativamente più elevati nelle femmine autistiche rispetto ai maschi, nei soggetti autistici 
più severamente compromessi indipendentemente dal sesso e nei bambini con esordio 
regressivo.  
Nel quinto e ultimo lavoro abbiamo studiato 36 soggetti autistici di cui abbiamo raccolto dati 
sui profili clinici di sviluppo insieme a campioni urinari sui quali sono state analizzate le 
concentrazioni di p-cresolo totale. Gli scopi di questo studio sono non soltanto di confermare 
un incremento di questo composto tossicp nei bambini con DSA ma anche di correlare i livelli 
di p-cresolo con i fenotipi clinici e con i profili di sviluppo. 
 
 
 1 
Introduction 
 
 
Autistic Disorder (AD), Asperger Syndrome (AS), and Pervasive Developmental Disorder Not 
Otherwise Specified (PDD-NOS; hereinafter referred to as Autism Spectrum Disorders, ASD) 
belong to a class of neuro-developmental pathologies characterized by a triad of early 
symptoms: qualitative impairments in social interaction and in social communication, and 
unusually restricted or stereotyped interests and behaviours (APA, 2000).  
In the last few decades, progress has been made as regards the earlier identification and 
diagnosis of children with ASD in their preschooler age (Rogers, 2001). Nevertheless, we still 
need further data about the accuracy and stability of early diagnosis, primarily on account of 
the low frequency of the disease in the general population and the dramatic impact of such a 
diagnosis on families (Charman and Baird, 2002). We also need data about the factors that 
predict different outcomes, in particular for the subgroup of children who have been observed 
to move off the ASD spectrum, even though these children still show developmental 
difficulties, particularly in language development (McGovern and Sigman, 2005). The 
pathogenesis of autism remains unclear in more than 90% of cases (Fombonne, 2003). In 
these cases the pathology is defined "idiopathic", i.e. triggered by interactions between 
multiple, unknown genes and environmental factors (Bailey et al. 1996; Trottier et al. 1999): 
these interactions may arguably affect the phenotypic variance of this complex disease.  
Several studies have assessed the fecal flora of autistic and control individuals, reporting an 
overgrowth of potentially pathogenic gut microbial species in a sizable subgroup of autistic 
patients, more consistently represented by Clostridia species (Finegold et al., 2002, 2010; 
Song et al., 2004; Parracho et al., 2005). Some of these bacterial strains, such as the 
Clostridium Difficile, express a p-hydroxyphenylacetate (p-HPA) decarboxylase which is able 
to push the fermentation of tyrosine up to the formation of a toxic, organic, and aromatic 
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compound: the p-cresol (Elsden et al., 1976; Selmer and Andrei, 2001). P-cresol travels in the 
blood while keeping mostly protein-bound (Bergé-Lefranc et al., 2010). Free plasma p-cresol 
and its conjugation derivatives, p-cresylsulfate and p-cresylglucuronide, are filtered by the 
renal glomeruli and can be found in small amounts in the urines of all individuals. These small 
amounts are argued to originate primarily from gut bacteria (Bone et al., 1976; Renwick et al., 
1988). 
Several recent studies have reported a high concentration of compounds presumably derived 
from the presence of Clostridia or other intestinal flora in autistic subjects (Shaw, 2010; Yap 
et al, 2010; Wang et al. 2011a,b). 
These results suggested that we assessed the urinary levels of p-cresol in autistic children so 
as to ascertain the role of this substance as a biomarker of the disease, of particular clinical 
phenotypes, and of developmental trajectories inside the complex and wide autism spectrum.  
 
Our research can be subdivided into three main domains: 
1) clinical studies on developmental trajectories in preschoolers with autism; 
2) studies on genetic factors that might have a role in the expression of the autistic phenotype; 
3) studies on environmental factors that might have a role in the expression of the autistic 
phenotype, with a focus on the role of urinary p-cresol. 
 
In particular, the following aspects will be addressed in this dissertation: 
Chapter 1 focuses on the new classification of ASD according to DSM 5 (Diagnostic and 
Statistical Manual of Mental Disorders 5th Edn; APA, 2013) reporting a review work on the 
relative literature as well as on the work of the DSM 5 Task Force on this topic. 
Chapter 2 focuses on the challenge of early ASD identification, with particular regards to the 
problem of the diagnostic stability of ASD diagnosis and its relationship with treatments in 
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preschoolers. The chapter also presents data from a longitudinal prospective study on this 
population. 
Chapter 3 focuses on the recent advances in autism genetics and reports on the results 
obtained from a recent association study on an Italian ASD cohort to which our research 
group has participated. The study has investigated the genetic markers associated with ASD 
from recent genome-wide and candidate gene association studies. 
Chapter 4 deals with the role of environmental factors and of the gene-environment 
interactions in autism. 
Chapter  5 describes all the studies that have already been conducted on the role of p-cresol 
in ASD and reports on the results of a multi-centric study to which our research group has 
also participated. 
Chapter 6 analyses the preliminary data from an ongoing doctoral study on p-cresol in 
preschooler children with ASD, in which the correlation between p-cresol levels and 
developmental trajectories and clinical phenotypes is being examined. 
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Chapter 1 
 
 
ASD in DSM 5 
 
 
1.1 The new classification of ASD according to DSM 5: a review work on the current 
literature on the topic with reference to the work of the DSM 5 Task Force 
 
During the last decade the DSM-5 Task Force has conducted an intense work based on a 
review of the literature and on the analyses of existing data in order to elaborate a new 
classification of the ASDs with new, more reliable and valid criteria for clinical and research 
purposes.  
During my doctoral study period I have worked with Prof. Muratori on a review work which is 
meant to describe the draft DSM-5 criteria for ASD diagnosis and to discuss the reasons for 
the changes made on the previous version of the manual (Santocchi and Muratori, 2012).  
We have examined the main questions and problems about the nosology of autism, with 
particular attention to the following topics: the importance of the concept of dimension for 
the purposes of neurobiology and nosology in psychiatric research; the core domains of the 
disorder: the DSM-5 draft criteria consider two domains for the diagnosis: A) social-
communication/social-interaction; B) restricted, repetitive behaviours and interests; the 
creation of the new diagnostic category of Social Communication Disorder (similar to the 
Semantic-Pragmatic Disorder) for subjects with social and communication deficits who do not 
show symptoms connected to the above-mentioned domain B; the elimination of language 
delay from the diagnostic criteria, as maintained by the DSM-5 Task Force in their 
conclusions, where such delay was not found to be specific of ASD, but regarded as a separate 
dimension that needs to be assessed for the clinical and neurobiological purposes; the 
creation of a unique diagnostic category for ASD and the elimination of the categories of 
 6 
Asperger Disorder and PDD-NOS, because empirical data do not account for the separation of 
the diagnostic categories; the age of onset of the disorder: the new criteria consider a wider 
range of ages when the disorder appears and claim that symptoms are present in early 
childhood but may not become fully manifest until social demands exceed limited capacities; 
the relationships between the new classification system and the recent advances in 
neurobiological findings: the subjects with ASD whose genetic condition has been diagnosed 
will receive a standard diagnosis of ASD, while their aetiological condition will be considered 
an associated characteristic. In this review work, each topic has been discussed with respect 
to the previous classifications, the questions which are still open and the following research 
guidelines. In the following section, I briefly report on those topics only that are relevant to 
this thesis.  
 
1.2 Brief Discussion on some relevant topics  
 
1.2.1 Diagnostic stability of autism and validity of the category of PDD-NOS  
 
Following the increasing possibility to diagnose autism since the first years of life, researchers 
have been prompted to investigate the outcome and stability of such earlier diagnosis in the 
subsequent ages. The short and medium term follow-up studies on diagnostic stability have 
globally shown high stability for AD diagnosis, while stability of PDD-NOS diagnosis has been 
reported to be much lower. Accordingly, children with ASD who have grown out of the autism 
spectrum (10-15% of the total children in most studies) are most likely to start out as PDD-
NOS. Generally, children who have moved out of the autism spectrum still show language 
disorders and/or other developmental disorders (Lord et al, 2006; Turner e Stone, 2007; 
Santocchi et al, 2010). Moreover, as children age, they tend to lose some of the severity of 
their illness, so that the diagnosis can change from AD to PDD-NOS. This problem seems to be 
caused by linking a diagnosis to the severity of manifestations of the symptoms and the DSM-
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5 Task Force has concluded that the current classification mixes the categorical definition 
with the severity of the disorder. The lower diagnostic stability of PDD-NOS with respect to 
AD suggests that PDD-NOS may represent a lower “dose” of autism, i.e. ASD, or that it may be a 
phenocopy, i.e. non-ASD associated with PDD symptoms, including genetic syndromes, such as 
Rett Disorder; it may also be the result of environmental exposure, such as fetal alcohol 
syndrome, or of plain measurement error. An other open question is: when PDD-NOS is no 
longer present, is the phenotype qualitatively the same while the associated impairment has 
become minimal (i.e., is it only the impairment that has disappeared?), or is there any 
evidence for true remission of autism? Long term follow-up and adult studies are essential to 
address the question of remission. Another criticism of existing diagnostic systems is due to 
the fact that several prevalence studies have found PDD-NOS to be more common than autism 
(Fombonne, 2003). Provided that atypical presentations of a disorder are more common than 
typical presentations, the validity and usefulness of the categorical concept becomes doubtful 
(Kraemer, 2008). One major change in DSM-5 is the proposal that there be a single category of 
behaviourally-defined ASD which encompasses all of the subtypes of PDD, currently described 
in DSM-IV. Such an approach in the new systems should clarify the unreliable, highly varied 
approaches that clinicians currently use to differentiate milder cases of autism from Asperger 
Syndrome and PDD-NOS (Lord et al., 2012) and would avoid the current phenomenon of the 
same individual receiving serial or sometimes even concurrent diagnoses of PDD-NOS, autism, 
and Asperger Syndrome, depending on their diagnostician’s knowledge and biases (Klin et al., 
2007; Miller & Ozonoff, 2000; Sharma, Woolfson, and Hunter, 2011). Arising out of this 
perspective is the formal acknowledgment that, at this point, a diagnosis of autism represents 
a name for a complicated set of behaviours believed to derive from yet unknown 
neurobiological causes and pathways, and that it does not correspond to the subcategories of 
ASD presently described by DSM-IV.  
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1.2.2 Diagnosis and neurobiological basis of autism   
 
So far, autism has been defined in DSM-IV exclusively in terms of behavioural criteria, but 
evidence for the biological basis of autism is growing with studies demonstrating variable 
support and variable explanatory power for biological variables. The increasing number of 
investigations demonstrates associations between ASD and genetic aberrations, as well as 
biological markers, neuroimaging results, head circumference, electrophysiological testing, 
and neuropsychological assessments. However, these findings are not sufficiently specific or 
cohesive enough to allow for either the identification of clinically meaningful subgroups or to 
be used as risk markers. In conclusion, according to DSM 5, individuals who meet criteria for 
ASD and with a genetic condition diagnosed, e.g. Fragile X or Rett Syndrome, will not receive 
different diagnoses, but a standard diagnosis of ASD, with these conditions regarded as 
associated features of ASD. This strategy also has the advantage of leaving room for new 
genetic and other biological findings that may shed light on aetiology in the future. 
 
1.2.3 The validity and reliability of diagnostic and assessment measures   
 
The revision of the diagnostic criteria has led, as a direct consequence, new questions 
about the validity and reliability of the existing measures for the assessment of the disorder. 
Lord and Jones (2012) have critically discussed this topic and asserted that many existing and 
widely used measures of diagnostic features in ASD do not yet have particularly strong test-
retest reliabilities across the most relevant age ranges (Lord et al., 1999; Scott et al., 2002). 
Concerns about validity are not limited to quick, easy to use screening measures, but also exist 
for more complex, difficult to administer diagnostic methods such as the ADOS and ADI-R (de 
Bildt et al., 2011). Although the two most commonly used research instruments have been 
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reported to be closely correlated (Kim and Lord, 2012) when samples include both children 
with ASD and those with other disorders; with more restricted samples including only 
children with clear ASD, especially those of children with near-normal or normal intelligence, 
correlations between instruments are close to zero (D. Bishop, 2011). Analyses using various 
combinations of ADI-R and ADOS indicate very poor specificity when any one measure, but 
not both, is positive (Risi et al., 2006) unless very high thresholds are set (Kim and Lord, 
2012). Both sensitivity and specificity are quite good when the instruments agree, but the 
notion of establishing continuous dimensions is limited by the minimal relationship between 
scores across instruments. Researchers are eager to have severity scores that quantify social 
deficits according to interval scales because these scales can be linked to other quantitative 
measures, i.e. imaging (Coutanche, Thompson-Schill, & Schultz, 2011). However, the measures 
that have domain scores for social interaction and repetitive/restricted behaviours, such as 
the ADI-R or the ADOS, do not provide this kind of score. Their total scores are additive and 
ranges are not based on true intervals. Severity scores proposed for the ADOS address this 
issue by tying severity to percentiles within populations of children with clinical diagnoses of 
non-spectrum, PDD-NOS/Asperger Syndrome and autism, but are still not true interval scales, 
particularly because most ‘typical’ children would be expected to score ‘0’ or ‘1’ (Gotham et al., 
2009). The importance of quantifying severity is a logic consequence of the elimination of the 
previous categories within the autism spectrum and of the need of obtaining information 
about individuals whose behaviours fall in the boundaries of the defined disorders. Finally 
there have recently been proposed alternative thresholds for clinical diagnoses (where the 
assumption is that sensitivity, or accurate identification of all positive cases, is of higher 
priority) and research diagnoses (where accurate exclusion of false positive cases may be of 
higher priority) (Kim and Lord, 2012; Lord et al., 2006). 
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1.3 The draft DSM 5 diagnostic criteria  
 
In DSM 5 the term ASD will replace the term PDD, since today, there are few defenders of 
‘PDD’ as nomenclature, though the original concept of expanding the concept of autism-
related disorders beyond the relatively narrow conceptualization of Kanner’s (1943) autism 
to include a broader group of individuals with language, play and social difficulties (Wing and 
Gould, 1978) was a bold and clinically very important step.  
The new and unique category, Autism Spectrum Disorder, will include AD, Asperger’s 
disorder, Childhood Disintegrative Disorder (CDD), and PDD-NOS.  Differentiation of ASD 
from typical development and other "non-spectrum" disorders will be done reliably and with 
validity; while distinctions among disorders have been found to be inconsistent over time, 
variable across sites and often associated with severity, language level or intelligence rather 
than features of the disorder. Because autism is defined by a common set of behaviours, it is 
best represented as a single diagnostic category that is adapted to the individual’s clinical 
presentation by inclusion of clinical specifiers (e.g., severity, verbal abilities and others) and 
associated features (e.g., known genetic disorders, epilepsy, intellectual disability and others). 
A single spectrum disorder is considered as a better reflection of the state of knowledge about 
pathology and clinical presentation. 
ASDs are placed inside the category of Neuro-developmental Disorders (ND) a new cluster 
that comprises disorders subcategorized in DSM-IV as Mental Retardation; Learning, Motor, 
and Communication Disorders; and Pervasive Developmental Disorders. This change answers 
to the need of organizing disorders in a way that would expressly recognize the possibility of 
shared features beyond symptomatic expression. Three domains become two: 
1) Social/communication deficits; and 2) Fixated interests and repetitive behaviours. Deficits 
in communication and social behaviours are inseparable and more accurately considered as a 
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single set of symptoms with contextual and environmental specificities. Delays in language 
are not unique nor universal in ASD and are more accurately considered as a factor that 
influences the clinical symptoms of ASD, rather than defining the ASD diagnosis. The new 
classification requires both criteria to be completely fulfilled in order to improve specificity of 
diagnosis without impairing sensitivity. Moreover, it provides examples for sub-domains for a 
range of chronological ages and language levels so that it should increase sensitivity across 
severity levels from mild to more severe, while maintaining specificity with just two domains. 
Besides, it requires two symptom manifestations for repetitive behaviours and fixated 
interests so that it should improve specificity of the criterion without significant decrements 
in sensitivity. The necessity for multiple sources of information including skilled clinical 
observation and reports from parents/caregivers/teachers is highlighted by the need to meet 
a higher proportion of criteria. The presence, via clinical observation and caregiver report, of 
a history of fixated interests, routines or rituals and repetitive behaviours considerably 
should increase the stability of autism spectrum diagnoses over time and the differentiation 
between ASD and other disorders. The reorganization of sub-domains should increase clarity 
and continue to provide adequate sensitivity while improving specificity through provision 
of examples from different age ranges and language levels. Unusual sensory behaviours are 
explicitly included within a sub-domain of stereotyped motor and verbal behaviours, 
expanding the specification of different behaviours that can be coded within this domain, with 
examples particularly relevant for younger children. With DSM 5 a thorough study of 
sensorial profiles will become compulsory and not more optional during the assessment of 
ASD subjects. In the new classification ASD is considered a neuro-developmental disorder and 
must be present from infancy or early childhood, but may not be detected until later because 
of minimal social demands and support from parents or caregivers in early years. A new DSM 
 12 
5 criteria (D) requires that symptoms together limit and impair everyday functioning. To such 
purpose, the Task Force has defined three severity levels of functional impairment. 
DSM-5 deal with boundaries just outside of ASD, outlining a new disorder within the 
Communication Disorders category rather than within ASD. Referred to as Social 
Communication Disorder, this category is intended to describe individuals who have 
significant social and communication difficulties similar to those in ASD, but without 
repetitive or restricted behaviours, rather than the full-range of ‘boundary’ conditions outside 
of ASD.  How many individuals fall into this group is not clear. The Social Communication 
Disorder as a category is similar to what Bishop described many years ago as Semantic-
Pragmatic Disorder (Bishop, 1989), with more explicit ruling out of children who meet the 
new ASD criteria. 
Preliminary data about the diagnostic validity of the new criteria have shown that they have a 
higher specificity but a lower sensitivity, in particular for subjects with higher IQ or milder 
symptomatology (Mc Partland et al, 2012; Mattila et al., 2011). 
 
1.4 Conclusions  
 
Ultimately, the first goal of a diagnosis must be clinical usefulness; nosology for the 
diagnosis of a disorder must address this aim (Kraemer, 2008). We should therefore ask 
ourselves whether the revision of diagnostic criteria has been accordingly oriented toward 
this goal. Despite the sure etio-pathogenic role of neurobiological factors and of gene-
environment interactions in autism, a behaviourally defined diagnosis remains the priority. 
Therefore, we agree with the attempt by DSM Task Force to secure a reliable and accurate 
clinical diagnosis. This is important so as to better define the role of treatments, and of the 
earlier ones in particular, in modifying the natural history of the disorder and it also amounts 
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to a solid basis for any research in clinic and neuro-biologic fields. It is important to obtain a 
stricter diagnostic definition of ASD as one category in the first place and accordingly 
investigate the relative phenotypes in the attempt to ground the research on the 
neurobiologic basis of the disorder. We should also like to stress the importance that 
diagnostic labels have for parents/caregivers and for the patients since the earliest 
communication of the diagnosis. In our clinical experience, the diagnostic label of PDD-NOS 
has shown to be a source of confusion for the families, whereas the concept of a pervasive, 
“not otherwise specified” disorder could remain ambiguous and generate in parents or 
clinicians the illusory and yet enduring expectation of a disorder that is not related to autism 
but to a more generic developmental disorder. As a consequence, such expectation is likely to 
account for different prognostic and therapeutic options. 
It is our opinion that the possibility of communicating the presence of an autism spectrum 
disorder earlier should help us gain a better understanding of the core features of the 
disorder itself and will also help parents and families shape their roles accordingly. The same 
applies to the diagnosis of Asperger Sindrome. In our experience, this syndrome is regarded 
for a long time by the parents as a “peculiarity”, or as an “excellence”, when compared to the 
profile of children with typical development. It follows that parents may lose sight of the fact 
that, even though children with this diagnosis show good linguistic and cognitive levels and a 
milder symptomatology, they still have a developmental disorder which significantly impairs 
several aspects of their daily adaptive functioning and emotional development. Finally, the 
introduction of one diagnostic category with specifiers for severity, language and cognitive 
levels may allow for a new diagnostic frame which enables a better understanding and 
definition of the diagnostic stability and developmental outcome in this heterogeneous and 
complex disorder.  
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Chapter 2 
 
Diagnostic Stability of ASD Diagnosis in Preschoolers 
 
2.1 Introduction 
Stability refers to the likelihood that a child will continue to attract an ASD diagnosis at 
follow-up. Several studies have assessed the stability of diagnosis from the second year of life 
(Charman and Baird, 2002). 
The first longitudinal studies of autism in preschool age date back to the Nineties. Gillberg et 
al. (1990) assessed 28 children of less than 3 y.o. for a possible ASD. At the follow-up 
assessment, performed after 6-140 months, all but 1 of the 21 subjects who had previously 
received a diagnosis of autism, received the same diagnosis.  
Lord (1995) studied a sample of 30 children brought to consultation for possible autism at 2 
years of age and evaluated trough ADI-R, ADOS-G, CARS and clinical diagnosis based on ICD-
10 criteria. The same assessment was repeated at 3 years of age. Only 1 child out of 30 moved 
off the autism spectrum receiving a diagnosis of receptive-expressive language disorder at 3 
years.  
In a study on 37 children, Stone and colleagues (1999) found good stability in clinical 
diagnosis of AD at 2 years and a half and re-assessed one year later, while they reported lower 
diagnostic stability in the initial diagnosis of PDD-NOS than the previous studies, given that 
4/12 children received a diagnosis of non ASD at the follow-up.  
The CHAT study (Cox et al, 1999) differed from the others because the subjects examined 
were not brought to clinical consultation directly and only prospectively identified as children 
who may have developed ASD. Also in Cox’s study, a diagnosis of autism or PDD given at 20 
months was stable at 42 months in all but 1 case (1/12). Nevertheless, PDD could be 
 16 
distinguished from other developmental delays at 20 months with less accuracy. Several 
children who subsequently received a diagnosis of PDD at the follow-up, had received a 
presumed diagnosis of global developmental delay or language delay upon their first 
assessment at 20 months of age (7/31). 
Moore and Goodson (2003) followed-up 20 children who were brought to consultation for 
suspect PDD at an average age of 2 years and 10 months, initially assessed through clinical 
judgement (based on ICD-10 criteria), ADI-R and psychometric tests, and subsequently re-
assessed with the same protocol at an average age of 4 years and 5 months. This study found 
higher stability of autism diagnosis (14/16, 87,5%), and, more in general, of PDD diagnosis. 
Eaves and Ho (2004) conducted a study on 49 2-year-aged children at risk of developing ASD 
(identified through the administration of such screening tools as PDDST and CHAT) who were 
subsequently evaluated at 2 years and a half and at 4 years and a half trough the 
administration of psychometric scales, CARS, VABS and clinical diagnosis based on DSM-IV 
criteria. Seventy-nine percent of the 49 subjects with suspected PDD at the screening received 
the same clinical diagnosis at the follow-up assessment while 40 children remained inside the 
autism spectrum. The diagnosis of 5 children (10%) changed from PDD-NOS to autism. Only 3 
children moved off the autism spectrum: of these 1 had received an initial diagnosis of autism 
and the other 2 had received an initial diagnosis of PDD-NOS. None of the 6 children who had 
been classified as non autistic at 2 years and a half, received a diagnosis of either PDD-NOS or 
autism at 4 years and a half.  
More recently, researchers studied diagnostic stability of autism also in children assessed 
before 2 years of age (Chawarska et al, 2007; Chawarska et al., 2009) and reported high 
diagnostic stability, of AD diagnosis in particular, also in these samples. 
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Moreover, some researchers (Charman et al., 2005; Turner et al. 2006; Lord et al. 2006; 
Turner and Stone, 2007) aimed at the identification of the possible predictive factors or 
indices of the outcome.  
Charman et al (2005) followed up 26 children since their first diagnosis of autism at 2 years 
(based on ICD-10 criteria) until the age of 7. They found that 85% of children retained the 
initial diagnosis. The standard assessment at 2 years (ADI-R, non verbal subscales of Griffiths 
Mental Development Scales, language assessment with CDI) was not predictive of the outcome 
at 7 years inside the same functioning domain, while the same assessment at 3 years was 
predictive of the outcome at 7 years. In fact, the scores obtained at the standard psychometric 
evaluations of NVIQ, of language skills and of severity of autism (assessed through ADI-R 
scores) correlated with the same outcome scores at 7 and with the quantification of adaptive 
functioning with VABS scale.  
Mc Govern and Sigman (2005) studied 48 children who had received a diagnosis of autism 
based on DSM IV criteria and CARS scores at an average age of 3 years and 11 months and 
who were re-assessed two times (first, at an average age of 12 years and 8 months, and a 
second time at 19 years) through both ADI-R and ADOS. Mc Govern and Sigman found that 
during adolescence 46/48 cases with an initial diagnosis of autism met lifetime criteria for 
autism diagnosis at ADI-R and 40/44 cases met criteria for ASD at ADOS.  
Turner et al. (2006) followed-up 25 children from their first diagnosis of autism at 2 years 
until the age of 9, and found that 89% of children retained the same diagnosis.  
Lord et al. (2006) reported on a wider sample of children (N=172) assessed at 2,5 and 9 years 
through ADOS, ADI-R and clinical diagnosis, and found very high stability in diagnoses of 
autism at 2 and 9 years, with only 1 child out of 84 who received a non PDD diagnosis at 9. On 
the other hand, this study found a lower stability in diagnoses of PDD-NOS, in that only 14/46 
children who had received a diagnosis of PDD-NOS at 2 years retained it at 9 years, while 
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more than a half received a diagnosis of autism and more than 10% received a non-PDD 
diagnosis.  
Turner and Stone (2007) studied a sample of 48 children assessed at about 2 years and re-
assessed at about 4 years. Diagnostic measures included Mullen Scales (MSEL; Mullen, 1995), 
ADOS-G, CARS and clinical diagnosis at the ages of 2 and 4, and ADI-R at the age of 4.  
Sixty-eight percent of 38 children with a clinical diagnosis of autism at 2 were still reported to 
fall into the autism spectrum at the age of 4. Nearly all the children who no longer met criteria 
for ASD diagnosis at 4 (11/12) still showed developmental difficulties (8 with Language 
Impairment –LI- and 3 with Developmental Delay/Language Impairment -DD/LI-). Only 40 % 
of 10 children with clinical diagnosis of PDD-NOS at the age of 2 were still reported to fall into 
the autism spectrum at 4. All the 6 children who no longer met criteria for an ASD diagnosis at 
age 4 continued to show developmental disorders (5 with LI and 1 with DD/LI). Children 
characteristics were examined to identify specific features at age 2 that differentiated the 30 
children who retained a clinical diagnosis of ASD from the 18 children who no longer met 
criteria for an ASD at age 4. Children who failed to meet diagnostic criteria for ASD at follow-
up were more likely to: 1) be 30 months or younger at initial evaluation; 2) have milder 
symptoms of autism, particularly in the social domain; and 3) have higher cognitive scores at 
age 2. No differences between children with stable and unstable diagnoses were found for 
amount of intervention services received.  
Ventola et al. (2007) examined 192 children aged 16–32 months, 150 of whom received a 
diagnosis of AD or PDD. Eighty-three percent of the 46 subjects with a diagnosis of AD or PDD 
at the first assessment were still reported to fall into the autism spectrum at the follow-up. 
Viewed another way, one in six infants who received an initial diagnosis of AD or PDD no 
longer met those criteria 2 years later. 
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Kleinman et al. (2008) studied 77 children assessed at 16-35 months of age and, 
subsequently, at 42-82 months of age. Diagnoses based on clinical judgment, CARS and ADOS 
were more stable over time than diagnoses based on ADI-R. According to clinical judgment, 15 
children (19%) moved off the autism spectrum by the second evaluation; none moved onto 
the spectrum. In particular, 85% of children who had received initial diagnoses of AD still fell 
into the autism spectrum at age 4, whereas 47% of children who had received initial 
diagnoses of PDD-NOS retained an ASD diagnosis at age 4. Similarly, fewer children with an 
initial diagnosis of AD than children with an initial diagnosis of PDD-NOS no longer met 
criteria for any developmental disorder (6% vs. 20%). 
The authors concluded that moving off the autism spectrum would reflect either true 
improvement based on maturation, or on intervention, or over-diagnosis at age 2. 
Fountain et al., (2012) described the longitudinal developmental trajectories of social and 
communication functioning in children with autism from the age of 2 to the age of 14 years 
finding six typical patterns of social, communication, and repetitive behavioural functioning. 
These trajectories displayed significant heterogeneity in developmental pathways, and 
socioeconomic factors were correlated with trajectory outcomes.  
Many studies, though not all of them, have suggested that intervention, the sheer amount and 
the type, can affect outcome (Howard et al., 2005; Green et al., 2010). Darrou et al. (2010) 
described developmental trajectories of children with autism assessed at the age of 5 years 
and 8 years and investigated their prognostic factors. They found two distinct outcome groups 
with more stability than change, two main risk factors (symptom severity and speech level) 
and two main protection factors (communication skills and person-related cognition) while 
the amount of intervention (in terms of number of hours) was not related to outcome. 
In a recent study Daniels et al. (2011) assessed diagnostic stability of ASD in community 
settings and identified factors associated with diagnostic instability using data from a national 
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Web-based autism registry. The authors used a Cox proportional hazards model to assess the 
relative risk of change in initial ASD diagnosis as a function of demographic characteristics, 
diagnostic subtype, environmental factors and natural history. 
Twenty-two percent of participants (n = 7,106) had a current diagnosis that was different 
from their initial one. This study, confirming the first hypothesis and consistent with the 
range of stability estimates reported in past clinical studies (Cederlund et al. 2008; Charman 
et al. 2005; Chawarska et al. 2007; Kleinman et al. 2008; Lord et al. 2006; Moss et al. 2008; 
Turner and Stone 2007) and in studies conducted in research settings, showed that ASD label 
stability depended in part on specific initial diagnosis, and PDD-NOS was found to be the least 
stable. The high rate of instability among an initial diagnosis of PDD-NOS was not entirely 
surprising given the ambiguous and widely debated nature of the APA’s current DSM-IV TR 
criteria, as well as changes in criteria between DSM-IV (APA, 1994) and DSM-IV-TR (APA 
2000) (Bristol et al. 1996; Mahoney et al. 1998; Szatmari 2000; Walker et al. 2004). The 
authors asserted that another possible explanation for the low diagnostic stability of both 
PDD-NOS and ‘PDD’/‘ASD’ could be that clinicians are assigning either diagnosis as a 
‘‘placeholder’’ for patients with mild or atypical ASD, particularly those younger than 5 years, 
waiting to see how the child develops and/or responds to early intervention and thus 
anticipating a label change. Findings from this study suggested that secular time may be 
influencing the stability of initial ASD diagnoses in community settings with children who 
were diagnosed most recently (after 2001) being more susceptible to diagnostic instability. 
The authors argued that the more likely explanation for this finding is that children are 
initially diagnosed at younger ages than they were in the recent past (Autism and 
Developmental Disabilities Monitoring Network 2006 Principal Investigators 2009), leading 
to longer intervals for natural history changes and/or early intervention, which then may 
impact ultimate diagnosis. 
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In a recent meta-analysis on the stability of the diagnosis of PDD-NOS (Rondeau et al, 2011) a 
pooled group included 322 AD and 122 PDD-NOS cases. The authors used percentage of 
individuals with same diagnosis at Times 1 and 2 as response criterion and showed that AD 
diagnostic stability was higher than PDD-NOS. When diagnosed before 36 months PDD-NOS 
bored a 3-year stability rate of 35%. Examining the developmental trajectories showed that 
PDD-NOS corresponded to a group of heterogeneous pathological conditions including 
prodromic forms of later AD, remitted or less severe forms of AD, and developmental delays 
in interaction and communication. As we see from this brief review, comparing the results of 
these studies is awkward, given the differences among samples, models and variables adopted 
and given the fact that a general consensus on the reliability of the diagnostic criteria and of 
the diagnostic tools is recent and still under revision in the scientific community. More 
recently, a systematic review of the diagnostic stability of ASD were carried out by 
Woolfenden et al. (2012). The authors considered 23 studies on diagnostic stability. Studies 
were included if: participants were children who had received a diagnosis of PDD, PDD–NOS, 
atypical autism, PDD-unspecified, Asperger disorder/syndrome or AD using a standardised 
diagnostic instrument or by using established diagnostic criteria, including DSM III–IV- IV TR 
(APA, 1994, 2000), or IDC-9/10 criteria (WHO, 1993, 2007) both at baseline and at follow up; 
the main focus of the study needed to be an observation over a period of 12 months or more 
of an initially defined population (with appropriate diagnostic label); studies were required to 
had at least 30 participants to differentiate case series from a cohort study; stability of 
diagnosis at follow up (change in diagnosis) must be measured with a DSM/ICD compatible 
diagnostic tool or multidisciplinary team or clinician assignment of DSM or ICD classification 
based diagnosis, included the ADI-R, the CARS, the ADOS-G, the Diagnostic Interview for Social 
and Communication Disorders (DISCO) (Wing et al., 2002); the Gilliam Autism Rating Scale 
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(GARS) (Gilliam, 1995) and the Developmental, Dimensional and Diagnostic Interview (3di) 
(Skuse et al., 2004). 
With respect to the stability of AD diagnosis, in studies of children with a baseline mean age 
under 3 years, 53 to 100% of children still had an AD diagnosis at follow up. Zero to 30% 
moved off the ASD spectrum altogether and a similar proportion moved to another ASD 
category. In studies of children with a baseline mean age of 3–5 years, 73 to 100% of children 
still had an AD diagnosis at follow up. Zero to 20% of children moved off the ASD spectrum 
altogether and a similar proportion moved to another ASD diagnosis. In studies of children 
with a baseline mean age over 5 years, 81 to 100% of children still had an AD diagnosis at 
follow up with 0–16% moving off the spectrum altogether and a similar proportion moving to 
another ASD category. If one only focused on the studies with the greatest number of low risk 
quality criteria this figure for overall diagnostic stability of Autistic Disorder was 85 to 89% 
remaining in that category. 
With respect to the stability of ASD diagnosis, in studies of children with a baseline mean age 
under 3 years, 22 to 100% of children still had another ASD diagnosis (that is ASD diagnoses 
not including Autistic Disorder) at follow up. Zero to 53% moved off the ASD spectrum 
altogether and a similar proportion moved to AD category. In children aged 3–5 years at 
baseline, 54 to 73% of children still had another ASD diagnosis at follow up. Zero to 5% 
moved off the ASD spectrum altogether and 27–41% moved to the AD category. In children 
with a baseline age over 5 years 14 to 76% of children still had another ASD diagnosis. Zero to 
23% moved off the ASD spectrum altogether and 0–86% moved to AD category. The 
diagnostic stability of an ‘‘other ASD’’ diagnosis for low risk of bias studies, over all age 
groups, was 14 to 61%. 
So, this systematic review has shown that overall a diagnosis of AD was a reasonably stable 
diagnosis with the highest quality studies estimating 88–89% stability, however in children 
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diagnosed in the preschool years this proportion has been reported to be as low as 53%. So, it 
is important when discussing a diagnosis of AD with a family of a newly diagnosed child that a 
minority of children, around 12–15% in the highest quality studies, will no longer meet 
diagnostic criteria for any ASD after a period of follow up, particularly those diagnosed in the 
preschool years with cognitive impairment. For other ASD (i.e., including PDD-NOS and 
Aspergers Disorder but not AD) this study found a highly variable pattern in stability between 
studies. When only the highest quality studies were assessed between 14 and 61% kept an 
‘other ASD’ diagnosis at follow up. In studies with a low risk of bias 61% of children in the 
under 3 age group were not diagnosed with an ASD at follow-up, and 81% in the over five 
year old group moved to a diagnosis of AD. This lack of stability in diagnosis is a challenge to 
clinicians in terms of making sense of the likely meaning of outcomes of a diagnosis for 
families, and for making intervention recommendations that are appropriate. This indicates 
that the broader diagnosis of another ASD (not including AD) is not a stable diagnostic 
category in children and is consistent with the findings of the meta-analysis of Rondeau et al. 
(2011), cited above, and discussions that have heralded a move toward the new DSM-5 
criteria (see Chapter 1 and Szatmari, 2011). Finally, this systematic review did not analyse 
predictors of outcome because although just under half of the studies did provide some 
analysis of possible predictors of the outcome of diagnostic stability the range of predictors 
was broad and varied between studies (including early intervention, communication, adaptive 
behaviour and cognitive impairment) and the types of analyses and variation in data 
presented meant that meaningful comparisons and syntheses were not felt to be possible by 
the authors. Nevertheless the 5 individual studies (Chawarska et al., 2009; Eaves & Ho, 2004; 
Jonsdottir et al., 2007; Lord et al., 2006; Turner & Stone, 2007) that measured early 
intervention as a possible predictor of diagnostic stability all found no difference between 
those children who had a stable diagnosis and those that did not. 
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There are still several open questions in the field of the variability of outcome and 
developmental trajectories of young children diagnosed as ASD and in the related topic of 
recovery from ASD, who has a very controversial and contentious history and is still under 
debate (Ozonoff, 2013). Recently, Fein et al. (2013) recruited 34 children with clearly 
documented early histories of ASD who no longer met criteria for any autism spectrum 
diagnosis and, even further, had lost all symptoms of ASD. They compared these children to a 
group of typically developing participants and they found no differences on multiple 
measures independent of the group classification process. They concluded that these results 
‘‘substantiate the possibility of optimal outcome,’’ demonstrating that some children with a 
clear early history and accurate diagnosis of ASD do indeed move into the entirely normal 
range of social and communication development later in childhood. The results provided by 
this work and other recent articles suggest that such optimal outcomes are not simply initial 
misdiagnoses, nor are they just hyperbole. As S. Ozonoff asserts in a recent editorial, “while 
many questions remain, the publication of Fein at al.’s article provides an initial scientific 
basis for talking openly of recovery as one possible outcome. We may not yet know how to get 
there, but now, we do know it is possible. The ultimate goal uniting both parents and 
professionals is to give each young child diagnosed with ASD the chance of this outcome, to 
know that no stone has gone unturned in the quest. We have exciting science ahead of us as 
we figure out the necessary ingredients of such outcomes” (Ozonoff, 2013). 
All these findings suggested that we assessed developmental trajectories of autism in 
preschooler age in order to check for the presence of a subgroup of children who grow out of 
the autism spectrum. We performed a preliminary observational longitudinal study 
(Santocchi et al., 2010) in order to examine diagnostic stability in children diagnosed with 
ASD in preschooler age and to identify child factors that contribute to variability in outcome.  
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Sixty-eight children, aged less than 6 years, diagnosed with AD or PDD-NOS according to DSM-
IV TR criteria, were assessed through 2 clinical evaluations (T0 and T1), in the course of 
which ADOS, CARS and psychometric tests were performed. 
Diagnostic stability for an ASD diagnosis was 87%; 9 children (13%) failed to meet diagnostic 
criteria for an ASD at T1: all of them received a diagnosis of PDD-NOS at T0, and 5 of them 
showed a diagnostic instability within 9 months from T0. No differences between children 
with stable and unstable diagnoses were found in ADOS or in cognitive test scores, while CARS 
scores were significantly higher in children later diagnosed with AD. Among the children with 
unstable diagnoses, all but 1 children continued to show a Language Disorder. This 
preliminary study provided support for diagnostic stability of the diagnosis of AD in 
preschoolers, more so far clear than for the diagnosis of PDD-NOS, that was unstable in 20% 
of cases, particularly for children assessed before 4 years. In more than 50% of cases, 
diagnostic instability was evident within 9 months from the first diagnosis. Two important 
limits of this study were the heterogeneity of the ages at the first and at the FU assessment 
and the heterogeneity of lengths of follow-up.  
During my doctoral study course we selected a more homogeneus sub-sample of subjects 
from this initial sample and we studied prospectively the outcome by setting more 
homogeneus lengths of follow-up and by limiting the recruitment to children under age 4 at 
the first evaluation.  
The aims of the present study (Santocchi et al, 2012) were: 
- Investigating the stability of autism diagnosis in preschoolers 
- Describing developmental profiles of autism at preschool age 
- Defining factors and predictive indices of different developmental profiles 
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2.2 Methods and materials  
 
2.2.1 Participants 
 
We examined a clinical database including longitudinal prospective data of 99 patients. All of 
them were referred to the PDD section of IRCCS Stella Maris Institute of Calambrone (Pisa) at 
preschool age (<6 years); all of them were subsequently re-assessed with at least one clinical 
follow-up evaluation (FU). In this database we included all the children who received a clinical 
diagnosis of AD, PDD-NOS or Asperger Disorder according to DSM IV-TR (APA, 2000) at the 
time of their first evaluation, no matter whether they concomitantly received or not a 
spectrum diagnosis through ADOS.  
In order to obtain a more homogeneous sample, we selected 60 patients from this database: 
their mean age at the time of the first evaluation (T0) was 36 months (SD: 6,57; range 23-48); 
their mean age at the time of the second evaluation (T1) was 61 months (SD: 7,75 months; 
range 47-78); the average of T0-T1 lapse was 25 months (SD: 2,91; range 19-33). At T0, 20 
children (33,33%) received a clinical diagnosis of Autistic Disorder (AUT) while 40 (66,67%) 
received a clinical diagnosis of PDD-NOS (hereinafter referred to as ASD). 
 
2.2.2 Procedures 
 
Materials 
ADOS (Lord et al, 2000) is a semi-structured assessment of communication, social interactions 
and relatedness, play, imagination, and stereotyped or repetitive behaviours. The assessment 
consists of social interactions planned to encourage social initiations and responses. There are 
also opportunities to engage in imaginative play. This measure yields scores in the social and 
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communicative domains. Besides, a combined score can be obtained by summing them. 
Diagnostic classification is carried out by exceeding cut-off scores in these three areas (social, 
communication, and combined). A child can eventually be classified as having AD or PDD-NOS, 
or as non-autistic. In our study, we also used revised ADOS algorithms (Gotham et al., 2007) 
and Calibrated Severity Scores (CSS; Gotham et al., 2009) generated by the new ADOS 
algorithms to evaluate the severity of autistic symptomatology. 
Griffiths’ Mental Development Scale (Griffiths, 1984), Leiter International Performance Scale – 
Revised (Roid e Miller, 1997), Wechsler Preschool and Primary Scale of Intelligence 
(Wechsler, 1990) were used to assess the cognitive levels of subjects.  
Since the subjects were assessed with different standardized psychometric test at T0 
depending on their language level and age, we assessed non-verbal IQ (nv IQ) according to the 
different tests and we consequently organized the results into 5 categories corresponding to 
as many cognitive levels plus one further category in which we included children who were 
not testable with standardized tests. 
Regarding the expressive language level at T0, we considered 4 categories by taking into 
account data from clinical evaluation of language, standardized tests and caregiver interviews. 
0) No words: < 5 spontaneous words 
1) Single words: > 5 spontaneous words 
2) Associations: combination of 2 or 3 words 
3) Phrases: phrases of 3 words as independent units (it corresponds to the language level for 
ADOS module 2). 
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2.3 Data Analysis 
Statistical analyses were performed with IBM SPSS Statistics 16. 
 
Table 1. Clinical and demographic characteristics of the sample. 
                           
 
   Total (60) AUT (20) ASD (40) 
      
Age T0 (SD)    36 (6,6) 36 (5,8) 36 (7) 
Age T1 (m; SD)   61 (7,8) 60 (6,5) 62 (8,4) 
T0-T1 (m; SD)   25 (2,9) 24 (2,5) 25 (3,1) 
      
 0 Not testable 17 9 8 
 1 nvIQ <50 0 0 0 
nv IQ T0 2 nvIQ 50-69 10 4 6 
 3 nvIQ 70-84 13 3 10 
 4 nvIQ 85-115 19 4 15 
 5 nvIQ >115 5 0 1 
      
 0 No words 33 15 18 
Expressive 1 Single words 23 5 18 
Language T0 2 Associations 4 0 4 
 3 Phrases 0 0 0 
      
 0 No words 10 7  3 
Expressive 1 Single words 18 8 10 
Language T1 2 Associations 11 1 10 
 3 Phrases 21 4 17 
      
ADOS T0   60 20 40 
  Module 1 60 20 40 
  Module 2 0 0 0 
  Mean CSS (SD) 5 (1,8) 6,5 (1,7) 4,3 (1,4) 
      
ADOS T1   60 20 40 
  Module 1 40 16 24 
  Module 2 20 4 16 
  Mean CSS (SD) 5,5 (2,1) 6,45 (1,5) 5 (2,2) 
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2.4 Results 
The FU showed 5 different developmental profiles (see Table 2 and Figure 1) which were 
matched for sex (chi-q = 0,796, df = 2, p= 0,672) and age (T0: ANOVA one –way, df = 2, F = 
0,161, p = 0,852; T1: ANOVA one –way, df = 2, F = 0,064, p = 0,938). 
 
Table 2. Developmental Profiles at FU. 
 
 
 
 
Figure 1.  Developmental Profiles at FU. 
                            
 
Most children with Autistic Disorder diagnosis at the age of 3 kept the same diagnosis at the 
age of 5, while some children with Autistic Disorder diagnosis at the age of 3 received a 
Developmental 
Profile 
Clinical 
diagnosis  
T0 
Clinical 
diagnosis T1 
 N (%) T0 Age 
m (SD) 
T1 Age 
m (SD) 
Sex 
M:F 
1 AUT AUT 17 (28,3)  36 (6) 61 (6) 15:2 
2 AUT ASD 3(5) 34 (7) 56 (8) 3:0 
3 ASD ASD 19(31,7)  36 (7) 61 (8) 16:3 
4 ASD AUT 12 (20) 37 (7) 62 (10) 11:1 
5 ASD NS 9 (15) 37 (8) 62 (9) 7:2 
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diagnosis of ASD at 5. None of them grew out of autism. Clinical diagnosis of Autistic Disorder 
was more stable than clinical diagnosis of ASD. 
We analyzed children with a diagnosis of AUT and children with a diagnosis of ASD at T0 
separately. We thus compared profile 1 to profile 2 (AUT groups), and profile 3 to profile 4 
and profile 5 (ASD groups). We also performed a correspondence analysis to compare the 
distribution of the 6 categories of the cognitive levels at T0 and at T1 in AUT and ASD groups 
(see Figure 2).  We found no significant difference between these two groups (AUT: T0, chi-q = 
6,928, df = 5, p = 0,226; T1, chi-q = 6,667, df = 5, p = 0,247; ASD: T0, chi-q = 9,963, df = 5, p = 
0,444; T1, chi-q = 10,269, df = 5, p = 0,417). The cognitive level at 3 did not differ within the 
AUT and the ASD developmental profiles groups. Nonverbal IQ did not prove to be a 
predictive factor of the outcome. 
 
Figure 2. nv IQ levels at T0 in the 5 developmental profiles.  
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We compared CSS at T0 in profile 1 vs. profile 2 and in profile 3 vs. profile 4 vs. profile 5. We 
found a significantly higher CSS in the profile 4 with respect to the profile 5 (ANOVA one-way 
df = 2, F = 4,156, p = 0,024, α = 0,05). 
Among children who received an ASD diagnosis at the age of 3, CSS was significantly lower in 
subjects who grew out of autism at the age of 5 than in subjects who received an AD diagnosis 
at the age of 5 (see Figure 3).  Therefore, CSS at the first evaluation proved to be a predictive 
factor of the outcome in ASD children.  
 
Figure 3. CSS at T0 in the 5 developmental profiles. 
 
                    
 
 
At T1, we found a significantly higher CSS in profile 4 than in profiles 3 and 5 (ANOVA one-
way df = 2, F = 15,321, p < 0,001, α = 0,05). CSS at T1 was significantly higher in children who 
moved from a diagnosis of ASD at 3 years of age to a diagnosis of AD at 5 than in children who 
either retained the ASD diagnosis or grew out of autism at 5 (see Figure 4). 
The changes in CSS occurred from 3 to 5 years proved to be a predictive factor of 
developmental trajectories.  
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Figure 4. CSS at T0 and CSS at T1 in the 5 developmental profiles. 
 
                                 
 
As regards children who grew out of autism at 5 years of age, ADOS diagnoses with revised 
algorithms at 3 were Non Spectrum in 77,8% (7/9) cases, while ADOS diagnoses with old 
algorithms were ASD in 77,8% (7/9) of cases (see Table 3). 
 
Table 3. ADOS Total scores, CSS, ADOS revised and old algorithm diagnosis in the 9 children 
who grew out of autism at T1. 
 
 
                         
ID    ADOS 
Total score 
CSS Revised algorithms  
        diagnosis  
Old algorithm  
  diagnosis 
8 10 3 NS ASD 
14 9 3 NS ASD 
20 8 2 NS ASD 
31 8 4 ASD NS 
36 7 3 NS ASD 
41 12 6 AUT ASD 
76 10 3 NS ASD 
91 7 3 NS ASD 
96 4 2 NS NS 
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As for the influence of treatment on the outcome, we collected data from 30 out of the 60 
children of the sample, using a semi-structured interview administered to the patients’ 
parents (Prosperi et al, 2013). In the light of the limited number of children, we could not 
carry out any statistical analysis of these data but did not fail to discuss the tendencies we 
could observe.  
The most frequently utilized treatments were psychomotor therapy and speech therapy: all 
the children but 2 received psychomotor therapy while over half of them (18) received speech 
therapy. Psycho-educative treatment was received by 7 out of 30 children, while 
psychotherapy was received by one child only. Nearly all the parents expressed the wish to be 
informed in detail and enabled to participate more actively in their children’s treatments. 
Children of AUT-AUT, ASD-ASD and ASD-AUT groups were younger at the beginning of 
treatments (29.1 months vs. 32.93 months) and received a greater amount of individual and 
psycho-educative intervention (552 and 368.8 hours vs. 384.36 e 66.7 hours, respectively) 
than children of AUT-ASD and ASD-NS groups. Children who received PDD-NOS diagnoses at 
T0 and AD diagnoses at T1 began their treatment when older than the others. Children who 
received AD diagnoses at T0 and PDD-NOS diagnoses at T1, began their treatment when 
younger and received a greater amount of dedicated treatment (individual treatment, parent-
mediated treatment, extra support at school) than the others. Interestingly, children who 
moved off the autism spectrum had not received more therapy than the others: the difference 
to be noticed is actually that they had begun treatment when younger than the others. 
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Table 4. Treatments received by the 5 subgroups-developmental profiles 
 
AUT-AUT AUT-ASD ASD-ASD ASD-AUT ASD-NS 
Mean Total 
hours of 
treatment 
  INDIVIDUAL TREATMENT 438,8 747 325,2 389,1 357,7 451,6 
PSYCHOMOTOR 
THERAPY 
222,4 317 152,34 260 101 210,5 
SPEECH THERAPY 102 0 71,9 133,3 48 71,04 
PSYCHO-EDUCATIVE 82 420 118 0 317,5 187,5 
PSYCHOTERAPY    
68  
(n =1) 
  
OTHER TERAPIES 35,4 20 
16  
(n = 1) 
5,14 
 46,6 
(n = 1) 
 
PARENT TRAINING 55,68 23 38,9 17,4 47,5 36,5 
SCHOOL ATTENDANCE 1660 1315 1995,5 1840,6 1894,7 1741,2 
SCOLASTIC  
SPECIAL SUPPORT 
1242,4 1226 1013,3 1077,4 525,3 1016,9 
SCHOOL ATTENDANCE/ 
SPECIAL SUPPORT 
1,34 1,07 1,97 1,71 3,61 1,94 
TOTAL DEDICATED 
TREATMENT  
1736,9 1996 1377,4 1483,9 930,5 1505 
AGE OF TREATMENT 
BEGINNING (months) 
30,7 25,5 33,8 34,3 32,7 31,4 
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2.5 Discussion 
 
In this study we analysed the outcomes of a diagnosis of autism in 3-year-old children through 
a follow-up carried out 2 years later (5-year-old children) where a considerable stability 
(85%) of the diagnosis was recorded. In particular, our study confirmed data of previous 
research reporting higher diagnostic stability of AD diagnosis when compared to ASD 
diagnosis (Woolfenden et al., 2012). As for possible predictive factors of the outcome of the 
diagnosis of ASD, our study showed higher ADOS Calibrated Severity Scores at 3 years in 
children who subsequently received a diagnosis of AD at 5 years, if compared to children who 
grew out of the autism spectrum at the same age. In contrast, non verbal IQ in AUT and ASD 
developmental profiles at 3 years did not differ. Several studies pointed out diagnostic 
stability of autism in preschool age but it was difficult to compare these studies to ours on 
account of the different ranges of age, inclusion criteria and measures of the samples. In 
Turner and Stone’s study (2007), children with unstable diagnosis at 4 years showed lower 
ADOS scores in the social interaction area, lower CARS total scores, and better IQ scores at the 
basal evaluation performed at 2 years compared to children with stable diagnosis.  
Finally, in our study, the amount of therapy did not seem to affect the patients’ outcome – this 
finding confirms Turner and Stone (2007) and Darrou et al. (2010) where the amount of 
intervention (in terms of number of hours) was not related to outcome – while the age when 
the treatment started is likely to affect the outcome. 
Interestingly, the developmental profiles we described in this study were very similar to those 
found in a recent survey by our research group which was meant to investigate the effects of 
‘as usual’ treatments in a multi-site study in Italy (Muratori et al, 2012). 
An observational research was conducted in order to evaluate the effects of early treatments 
on the outcomes of toddlers diagnosed with ASD, comparing (a) behavioural interventions vs. 
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development-oriented interventions; (b) children attending school vs. non-attenders; (c) 
children with parents involved in treatments vs. children whose parents were not involved in 
treatments. Seventy children aged 18 - 48 months and diagnosed with ASD were evaluated by 
blind researchers at baseline and after six months of interventions using ADOS, Griffiths 
Mental Developmental Scales, Vineland Adaptive Behaviour scales, and questionnaires filled 
out by parents (Mac Arthur inventory; Social Communication Questionnaire; Parenting Stress 
Index; Child Behaviour Check List). All children were referred to community providers for 
common available interventions. At endpoint, most children still received an ADOS diagnosis 
of ASD, even though 21 of them moved from AD to ASD diagnosis and 3 moved off the autism 
spectrum (see fig. 5).  
The children were classified into 2 subgroups corresponding to the subtypes of treatments 
received: behavioural intervention (ABA; PRT; DTT: 30 subjects) and development-oriented 
intervention (DIR, Denver, TED; Psicomotricity:, 40 subjects). The 2 groups significantly 
differed only in the average number of treatment hours (development-oriented intervention: 
9 hours/week vs behavioural intervention: 14 hours/week; t = 3,78; p = ,028) and in ADOS 
Total score at T0 (development-oriented: 15 ± 2,23 vs. behavioural: 17,8 ± 1,51; t = 5,83;  
 
Figure 5. Flow-Chart on changes in ADOS diagnosis between T0 and T1 (from Muratori et al., 
2012) 
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P =0.006). The ANOVA controlled for time of treatment and for ADOS total score, showed 
significant differences in PSI Total and in PSI Child Domain scores only.  
Children with parents involved in the treatments had significantly better outcomes than 
children whose parents were not involved; children who attended school had significantly 
better scores at ADOS Social Interaction Scale and at VABS Daily Ability Scale than the 
children who did not attend school. 
  
2.6 Conclusions 
 
Firstly, these results confirm that when we communicate for the first time a diagnosis of 
autism we can consider it as a still open and dynamic condition, with also a possible 
favourable outcome. That’s more true for earlier diagnosis, even before the period of life 
considered as reliable for diagnosis and placed around 36 months of life. Secondly, at the 
beginning of treatments we have not to set aside two important aspects of the interventions 
as the active involvement of parents in treatments and the opportune start of school attending 
with an individual support teacher. Thirdly, it is necessary to adapt the treatments to the 
needs and the specific developmental profiles of each child, considering the range of actually 
disposable treatment options. Our research indicates that there is not a specific treatment 
technique that is more effective than the others but rather the opportune and intensive start 
of coded therapeutic options seems to be more effective.  
The developmental profiles we described in all our studies were interestingly very similar 
each other; moreover, these outcome profiles seemed not strictly related to the treatments so 
they may arguably subtend different clinical phenotypes with distinct neurobiological bases. 
Therefore, we are interested in the clinical implications of these data, in that the use of 
Revised ADOS algorithms and CSS could improve diagnostic and prognostic strength of our 
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clinical assessment, even in the framework of the new DSM 5 diagnostic classification of ASD. 
Moreover, we are interested in the possible use of these data for the purposes of research on 
neurobiological markers of ASD and on endophenotypes.  
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Chapter 3 
 
Genetic Markers Associated with ASD 
 
3.1 Introduction  
Before the 1970s, autism was not widely appreciated to have a strong biological basis. 
Instead, various psychodynamic interpretations, including the role of a cold or aloof style of 
mothering, were invoked as potential causes. The importance of genetic contributions became 
clear in the 1980s, when the co-occurrence of chromosomal disorders and rare syndromes 
with the ASDs were noted (Blomquist et al. 1985). 
Subsequent twin and family studies provided additional support for a complex genetic 
aetiology, but these were limited by the lack of uniform diagnostic criteria. The development 
of validated diagnostic and assessment tools in the early 1990s, most notably the ADI-R and 
the ADOS, addressed these concerns and these tools have proven crucial to the advancement 
of international research into the ASDs. 
Several lines of evidence support genetic factors as a predominant cause of the ASDs. First is 
the growing body of literature demonstrating that mutations or structural variation in any of 
several genes can dramatically increase disease risk. Second, the relative risk of a child being 
diagnosed with autism is increased at least 25-fold over the population prevalence in families 
in which a sibling is affected (Jorde et al., 1991). Third, siblings and parents of an affected 
child are more likely than controls to show subtle cognitive or behavioural features that are 
qualitatively similar to those observed in probands (the broader autism phenotype) (Bolton 
et al., 1994; Bishop et al., 2004); this is consistent with the segregation of quantitative sub-
threshold traits within these families (Bolton et al, 1994; Bishop et al, 2004). Fourth, 
independent twin studies, although small, indicate that concordance rates for monozygotic 
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twins (70–90%) are several-fold higher than the corresponding values for dizygotic twins (0–
10%)(Bailey et al, 1995; Steffenburg et al, 1989). 
Central to the question of how genetic variation comes to influence phenotypic presentation is 
whether distinct aspects of ASDs are subject to independent genetic modulation or, 
alternatively, they are sensitive to largely overlapping risk factors. Recent work in a 
community-based cohort revealed that, despite high heritability values (>0.64) for social, 
communication and repetitive and/or restrictive domains (Ronald et al., 2006), only modest 
co-variation was observed between them. 
Two contrasting but valid and potentially compatible paradigms dominate current thinking 
regarding the role of genetic variation in ASD susceptibility. The independent heritability of 
distinct ASD core domains supports the importance of common variation in disease risk and 
phenotypic presentation. At the same time, the fact that functional disruption of single 
molecules seems to be sufficient to cause disease suggests that the identification of rare 
variants is also important. The primary technical approaches used in ASD research are largely 
rooted in one of these two models (Abrahams and Geschwind, 2008). 
Chromosomal abnormalities offered the first glimpse at the potential role of rare variants in 
ASD susceptibility (Vorstman et al, 2006). It is estimated that cytogenetically identified 
lesions are present in 6–7% of ASDs (Marshall et al, 2008), although this proportion is higher 
in dysmorphic populations with MR. Inherited duplications involving the chromosomal region 
15q11–15q13 are among the most common cytogenetic abnormalities in the ASDs, accounting 
for 1–2% of cases. 
The clues obtained by these studies have proven important in our understanding of ASD 
aetiology. Within the 15q11–15q13 locus, ubiquitin protein ligase E3A (UBE3A) and 
gammaaminobutyric acid A receptor beta 3 (GABRB3; an inhibitory neurotransmitter 
receptor) are currently thought to be central. Similarly, deletions involving 22q13 have been 
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recognized for some time, but the important role of SH3 and multiple ankyrin repeat domains 
3 (SHANK3; a synaptic adaptor protein) was appreciated only after resequencing and CNV 
analysis (Moessner et al, 2007). Deletions involving 2q37 are also common, having been 
observed in more than 70 cases. Other regions that are implicated in the ASDs by 
chromosomal abnormalities in multiple patients include 5p15, 17p11 and Xp22 (Vorstman et 
al, 2006). As a result of the large regions that are typically isolated by analysis of 
chromosomal anomalies, these methods cannot alone inform us about particular molecular 
functions that might be impaired in the ASDs. 
Considerable insight into potential candidate genes was obtained from the study of 
molecularly defined syndromes in which ASD was observed at higher than expected 
frequencies. Several of these conditions, such as fragile X syndrome and Rett syndrome, 
suggest synaptic dysfunction as a unifying aetiology (Zoghbi et al, 2003), whereas others, such 
as Tuberous Sclerosis, highlight the diversity of signalling pathways that seem to be related to 
the ASDs. 
Although these ASD-associated syndromes involve genes with multiple molecular functions, it 
seems increasingly plausible that they converge on common biological pathways or brain 
circuits to give rise to ASDs (Geschwind and Levitt, 2007). 
The introduction of cost-effective re-sequencing has made it possible to build on cytogenetic 
studies and obtain evidence for the involvement of specific candidate genes in the ASDs. The 
identification of rare ASD-linked mutations in neuroligin 3 (NLGN3) and neuroligin 4 X-linked 
(NLGN4X) was an important advance linking the ASDs to specific molecules that are involved 
in synaptic function (Jamain et al, 2003). 
Mutations in SHANK3, the product of which interacts with neuroligins (Meyer et al, 2004), 
were identified by a similar route, and provide further evidence for the potential role of 
defective synaptogenesis in ASDs 
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Beta-neurexins also interact with neuroligins (Boucard et al, 2005) and as such are 
compelling candidates for involvement in the ASDs. 
A recessive frameshift mutation was also identified in contactin associated proteinlike 2 
(CNTNAP2), a member of the neurexin family (Poliak et al, 1999), in Amish individuals 
presenting with cortical dysplasia-focal epilepsy syndrome, a congenital disorder 
characterized by seizures and language regression. Notably, two-thirds of affected individuals 
also met the criteria for an ASD (Strauss et al, 2006).  
The identification of CNV in addition to single-base-pair polymorphisms (SNPs) has opened a 
new window on human genetic variation (Sebat et al, 2004). De novo and inherited CNV are 
emerging as important causes of ASDs, either as rare variants that strongly modulate risk or 
as potentially new syndromes linked to the ASDs. 
The increased resolution of array-based approaches suggests that the proportion of cases that 
might ultimately be attributable to rare structural variants is probably much higher than the 
6–7% identified by standard cytogenetics. 
In addition to the identification of novel loci that are important for our understanding of the 
ASDs observed differences in the extent of de novo variation between controls (1%), multiplex 
ASD families (2–3%) and simplex ASD families (7–10%) (Sebat et al, 2004; Marshall et al, 
2008) are consistent with other complex inherited diseases in which different genetic 
mechanisms are observed in sporadic compared with familial cases. These results are also 
relevant to the notion of the broader autism phenotype that is observed in the general 
population. 
Given that many of these rare variants span many genes and have only been observed in a 
single proband, much work is required to determine the subset causally related to disease. 
For some of the very rare, virtually unique, mutations even large sample sizes will not be 
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sufficient to demonstrate statistical association, although the biological significance of the 
mutation may be clear. 
Overall, none of the molecules or syndromes currently linked to the ASDs have been shown to 
selectively cause autism. Instead, each seems to result in an array of abnormal 
neurobehavioural phenotypes, including autism, Asperger syndrome, non-syndromic MR and 
other neurodevelopmental abnormalities. 
An understanding of the contribution of common variation — and the manner by which rare 
variants could modulate presentation even in cases with rare ‘major’ mutations — is an 
important future step. 
Substantial effort in autism genetics over the last 10 years has been focused on genetic linkage 
analysis using an affected sibling-pair design in multiplex families. Most studies have 
identified linkage regions reaching the threshold of suggestive linkage at best. Loci on most 
chromosomes have been suggested to harbour ASD risk loci, but only a minority have been 
independently identified. To date, only loci on 17q11–17q21 and 7q have been replicated at 
levels that could be considered genome-wide significant (Badner et al, 2002, Cantor et al, 
2005). The lack of genome-wide significant results in most published linkage studies is 
probably a consequence of the small effect size that is attributable to any particular gene. 
It is therefore not surprising that efforts to reduce heterogeneity by subsetting the sample 
according to specific phenotypes (Stone et al, 2004) and refining phenotype definitions, have 
improved linkage signals. For example, subsetting by sex of proband (Cantor et al, 2005), 
language (Buxbaum, 2001) or other neurobehavioural features such as autistic regression or 
behavioural inflexibility (Molloy et al, 2005) has increased signals relative to non-stratified 
samples, including identification of genome-wide significant loci (Cantor et al, 2005). 
Given these successes, additional heritable phenotypes such as macrocephaly, structural 
features defined by magnetic resonance imaging, or the presence of seizures or 
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electroencephalographic abnormalities might offer promise in defining subgroups of 
probands with autism (Abrahams and Geschwind, 2008).  
In QTL mapping, autism endophenotypes are studied as opposed to affection status. The 
premise underlying a QTL approach complements models in which key aspects of the ASDs 
might be at one end of a continuum of normal behaviour and cognition (Abrahams and 
Geschwind, 2005). Such work also recognize that the diagnostic categories used in clinical 
practice might not properly represent underlying genetic risk. 
Micro-array studies are beginning to provide important insights into molecules and pathways 
that might be dysregulated across the ASDs and within individual subtypes of PDD. 
Nishimura and colleagues (2007) showed that gene expression can distinguish among ASD 
cases caused by known genetic lesions and identify common pathways that were validated 
both in neural tissues and cases of idiopathic autism. This work defined 68 molecules that are 
differentially expressed in cells from fragile X syndrome and 15q duplication patients with an 
ASD relative to controls and identified cytoplasmic FMR1 interacting protein 1 (CYFIP1; an 
interactor of fragile X protein) and janus kinase and microtubule interacting protein 1 
(JAKMIP1, also known as MARLIN1, which traffics gamma-aminobutyric acid receptors) as 
providing a direct molecular link between the two conditions. 
Several other studies have profiled gene expression in peripheral blood (Baron et al., 2006; 
Bittel et, 2007) to identify biomarkers or patho-physiological pathways in ASDs and related 
neurodevelopmental disorders; these await validation using independent methods and 
samples. 
The identification of multiple rare mutations has implicated numerous genes of diverse 
function in the aetiology of the ASDs. Although causality remains to be demonstrated in most 
cases, a substantial subset seems to be important in modulating disease risk. 
Given variable expressivity and incomplete penetrance among individuals carrying the same 
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rare mutation, understanding the manner by which these rare variants interact with common 
alleles remains important. 
Also important, and immediately tractable, is the question of whether ASDs of different 
aetiologies share common molecular mechanisms or pathways, and, if they do, whether the 
relationship between the underlying genes be understood (Krauthammer et al., 2004; Aerts et 
al, 2006). Related to the heterogeneity in the ASDs, and discussed above, is the absence of 
clarity surrounding the specifics of the relationship between the ASDs, MR and other 
neuropsychiatric conditions. These concepts reinforce the idea that current clinical notions of 
boundaries between neuropsychiatric disorders need not be representative of the underlying 
genetic or biological etiologies (Abrahams and Geschwind, 2008). 
 
Recently, three common markers have been identified in different genome-wide association 
studies: rs4307059 at 5p14.1 between neuronal cell-adhesion molecule genes (CDH9 and 
CH10); Ma et al, 2009; Wang et al, 2009); rs10513025 at 5p15.31 between the semaphoring 
(SE-MA5A) and bitter taste receptor (TAS2R1) genes (Weiss et al., 2009); and rs4141463 at 
20p12.1 within the MACRO domain containing 2 (MACROD2 gene) (Anney et al, 2010). In 
addition, Carayol et al. (2010) recently performed a combined analysis of four common low-
risk genetic variants in family samples: rs 2292813 in the mitochondrial aspartate/glutamate 
carrier gene (SCL25A12; Ramoz et al, 2004; Segurado et al, 2005), rs35678 in the ATPase, Ca2 
transporting, plasma membrane gene (ATP2B2; Carayol et al, 2009; Carayol et al, 2011), 
rs6872664 in the paired-like homeodomain transcription factor 1 gene (PITX; Philippi et al, 
2007), and rs1861972 in the homeobox transcription factor ENGRAILED2 gene (EN2; Gharani 
et al, 2004; Benayed et al., 2005), indicating that the accumulation of multiple alleles 
calculated as a genetic score may be a useful strategy for assessing autism risk in siblings of 
affected individuals. 
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The objective of this study (Prandini et al., 2012) was to test whether the aforesaid genetic 
markers are associated with ADSs in newly collected Italian ASD cohort and, if so, whether a 
combined analysis of risk alleles could be proposed. 
 
3.2 Methods and Materials  
 
3.2.1 Family samples 
The Italian Autism Network (ITAN) study is a large national multi-centric project, initiated by 
SmithKline Foundation to which our research group participated, with the aim of collecting 
biological materials (DNA, RNA, plasma and lymphoblastoid cell lines) and clinical and 
functional data from ASD probands, their parents, and their relatives. At present a total of 824 
individuals (251 families) have been assessed. 
Inclusion criteria were: I) the patient meets DSM IV criteria for Autism, Asperger Disorder or 
PDD NOS; II) reaches the score cut-off in ADI-R and ADOS; III) is at least 4 years old at the 
time of entering the research project; IV) has at least one parent or legal guardian giving 
voluntary written consent for him/her to participate in the research project, and V) gives 
his/her assent when possible.  
Exclusion criteria included diagnosis of Rett syndrome or Childhood Disintegrative Disorder, 
history of serious head injury, encephalitis or tumors, severe mental retardation (IQ < 20), 
and age more than 18.  
To ensure the reliability of the diagnosis, an ADI-R interview with a parent or a caregiver and 
an ADOS test with patients were used. They were carried out by trainer interviewers at each 
recruiting center. Each proband was assessed for clinical history and underwent physical and 
neurological examinations, genetic karyotyping for Fragile X, a neurophysiological 
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examination (EEG, ideally awake), and neuroradiological imaging (investigation of acquisition 
of a previous MRI scan of adequate quality). Blood samples were collected from each patient 
and from family members in 13 Italian clinical centers and were sent to the Department of 
Life and Reproduction Sciences, University of Verona for biobanking.   
3.2.2 Genotyping  
A total of 746 individuals from 227 families (233 probands, 201 boys and 32 girls; 423 
parents and 90 siblings) were genotyped using TaqMan allelic discrimination assays for seven 
common SNPs: rs2292813 (SLC25A12 gene), rs35678 (ATP2B2 gene), rs4307059 (between 
CDH9 and CDH10 genes), rs10513025 (between SEMA5A and TAS2R1 genes), rs6872664 
(PITX1 gene), rs1861972 (EN2 gene), and rs4141463 (MACROD2 gene).  
3.2.3 Statistical analysis 
The advantage of the family-based approach is that provides robustness against spurious 
associations caused by unmeasured population stratification. The association analysis was 
conducted using the case/pseudocontrol approach, which is a general framework for family-
based association analysis (Cordell, 2004). The method yields reliable results in families 
having multiple affected sibs and is based on conditional logistic regression, using the case 
and three ‘pseudocontrols’ derived from the untransmitted parental alleles. Statistical 
analysis were carried out under the hypothesis of an additive model so that the allele effects 
could be interpreted as log of odds ratios. The statistical model also included a dominance 
effect parameter measuring deviation from the simpler additive model, and its significance 
was estimated using a likelihood ratio test. Associations were considered statistically 
significant when they showed a P-value of less than 0,05. 
 
 48 
3.3 Results  
No association was found for any of the seven SNPs when tested for an additive effect, 
indicating that this effect per se does not fit the true underlying genetic susceptibility model. 
Considering a deviation of the additive effect, the dominance effect, we observed significant 
results only for two of seven markers: rs4307059 (LRT, P = 0.0129) and rs35678 (LRT, P = 
0.0009). The dominance contribution of marker rs4307059 was due to a positive effect of 
allele T over C (odds ratio: 1.758, SE=0.236; P-value  = 0.017) in the heterozygous individuals, 
suggesting that is sufficient to carry at least one copy of allele T to increase the risk of ASDs. 
For marker rs35678, individuals with genotype TC were at lower risk when compared with 
CC or TT individuals (odds ratio: 0.528, SE=0.199; P-value=0.0013), indicating that the 
homozygotes are at higher risk. No interaction effect between the two genetic markers was 
observed. 
 
3.4 Discussion 
The association of rs4307059 at 5p14.1 was previously observed in other large studies (Wang 
et al., 2009; Ma et al., 2009; St Pourcain et al., 1010), all of them indicating T as the risk allele, 
as observed in the present study. The genetic model underlying the susceptibility linked to the 
rs35678 marker is intriguing as the effect of the two homozygotes was significantly different 
from that of the heterozygotes. It is difficult to interpret the biological rationale of having 
protected heterozygotes compared with homozygotes. This could be the underlying rationale 
behind the fact that rs35678 is not the exact polymorphism conferring autism vulnerability at 
the ATP2B2 locus but is a proxy exerting an effect in conjunction with other SNPs on the same 
gene or with other genetic/environmental factors. A similar line of evidence is provided by 
Carayol et al. (2011), whose novel data suggest an association of the ATP2B2 gene (with 
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rs3774180, rs2278556, and rs241509 markers) with the rs35678 marker that was marginally 
significant under an additive, recessive or sex-stratified model (Carayol et al. 2011). 
The rs4307059 marker is located between CDH9 and CDH10 genes encoding neuronal cell-
adhesion molecules and has been associated with social communication spectrum phenotypes 
in the general population (St Pourcain et al, 2010). The rs35678 marker is located in the 
ATP2B2 gene, which encodes for a brain-specific calcium pump, and it has been linked to 
language delay (Carayol et al. 2010). 
Therefore, a preferential allele transmission of two markers located at loci previously 
associated with social and verbal communication skill has been confirmed in patients of a new 
ASD family sample and so we propose that these association might contribute to the 
variability of two essential endophenotypes of ASDs. 
  
3.5      Conclusions 
The present study cannot confirm the advantage in genotyping at multiple loci to assess the 
risk of ASD in siblings of affected individuals, whereas it replicates the association of common 
genetic variants located on 3p25.3 and 5p14.1 with ASDs in a novel family-based study.  
As we discuss above and as Abrahams and Geschwind assert (2008), the lack of genome-wide 
significant results in most published linkage studies is probably a consequence of the small 
effect size that is attributable to any particular gene. 
Moreover, we must aim to integrate existing and emerging genetic candidates into our 
understanding of human brain function. One of the most important remaining unsolved issues 
is the understanding of the relationships between genetic variation and phenotype. 
A first hypothesis to explain this phenotypic heterogeneity is that a secondary insult is 
necessary during development to result in the phenotype, as in the “two-hit model” proposed 
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in developmental delay. Several studies recently supported the existence of such a 
combination of rare variants in some cases. Another hypothesis is the contribution of both 
rare and frequent variants. This would be consistent with the observations of broader sub 
threshold traits in siblings (Abrahams and Geschwind, 2008).   
The last hypothesis, which is not mutually exclusive with other hypotheses, is the contribution 
of environmental factors which modify the phenotype. 
So, an important question for future work will be to clarify how environmental and genetic 
factors interact to influence risk and presentation of ASD. 
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Chapter 4 
 
Environmental Factors and Gene-Environment Interactions in Autism 
 
4.1 Indirect evidence suggesting a contribution of environmental factors 
 
4.1.1 Prevalence 
Prevalence studies of ASD conducted in recent years have been the source of an important 
debate because of a steady and highly significant increase of estimates of the total prevalence 
of PDD. However, another study suggested that diagnostic substitution, especially for the most 
severe cases, and better ascertainment, especially for children at the less severe end of the 
spectrum, explain only a part of the linear increase observed in the California registry (King 
and Bearman, 2009). While the hypothesis of an increased incidence in relation to 
environmental factors could not be confirmed nor excluded definitely, studies using the same 
protocol several years apart are required (Fombonne, 2009). 
 
4.1.2 Immune dysfunction 
Several lines of evidence support the hypothesis of immune changes in autism. 
First, several studies have shown abnormalities in the peripheral immune system such as T-
cell dysfunction, autoantibody production, increase in the number of activated B cells and NK 
cells, and increase in pro-inflammatory cytokines (Gupta et al, 1998; Singh et al, 1997; 
Ashwood et al, 2011). Moreover, a landmark study provided evidence for micro-glial and 
astro-glial activation in brain of patients with ASD (Vargas et al, 2005). Another study 
consistently reported microglial activation in the dorsolateral prefrontal cortex in brains of 
patients with ASD (Morgan et al, 2010). This neuro-glial response may result from either a 
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primary disturbance of neuro-glial function or unknown factors that disturb prenatal or 
postnatal CNS development (Chaste and Leboyer, 2012). 
 
4.1.3 Transcriptome 
The first comprehensive gene-expression analysis of brains of patients with ASD recently 
reported differences in transcriptome organization between autistic and normal brain 
(Voineagu et al, 2011). 
The authors identified two discrete modules of coexpressed genes associated with autism. 
While the first module, which is related to synaptic function and neuronal projection, was 
underexpressed in autism cases, the second module, which was enriched for immune genes 
and glial markers, was overexpressed. 
The authors did not find any evidence for a genetic etiology for the upregulation of the genes 
of the second module, suggesting that it is probably a nongenetic, adaptive, or environmental 
process. 
 
4.1.4 Epigenetic dysregulation in autism 
Epigenetic marks define chromatin state and regulate the expression of many genes without 
affecting primary DNA sequence. These include DNA methylation, and histone methylation 
and acetylation, and can be modified in response to either genetic mutations or 
environmental exposure. Several elements indicate the existence of epigenetic dysregulation 
in autism (Chaste and Leboyer, 2012). 
Although most of the epigenetic modifications are underpinned by genetic mechanisms, the 
evidence of the contribution of epigenetic dysregulation in autism raises the issue of the role 
of epigenetic modifications by environmental factors such as assisted conception, since in 
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vitro fertilization and ovulation induction can result in abnormal methylation and 
dysregulation of imprinted genes (Fernandez-Gonzalez et al, 2004). 
 
4.2 Direct evidence for the contribution of environmental factors 
 
4.2.1 Prenatal and perinatal factors 
In a recent meta-analysis the main factors are maternal gestational diabetes, maternal 
bleeding during pregnancy, and maternal medication (Gardener et al, 2009). Moreover, 
increased risk was also found for first-born children compared with children born third or 
later, and, in Nordic countries, for offspring of mothers born abroad. Exposure to intrauterine 
infections was associated with a significant increase in risk for autism. In another meta-
analysis focusing on the perinatal and neonatal period (Gardener et al, 2011) the same 
authors identified several potential risk factors, the main being fetal presentation, umbilical-
cord complications, fetal distress, birth injury or trauma, multiple birth, maternal 
hemorrhage, summer birth, low birth weight, small for gestational age, low 5- minute Apgar 
score, meconium aspiration, neonatal anemia, ABO or Rh incompatibility, and 
hyperbilirubinemia while preterm birth was not associated with the risk of autism. 
 
4.2.2 Socioeconomic status 
Although one study did not find any association between risk of autism and socioeconomic 
status (Larsson et al, 2005) including maternal education level, the latter may significantly 
influence the age of first single words (Grandgeorge et al, 2009). Moreover, as already 
mentioned, autism risk was found to be significantly increased for the offspring of mothers 
born abroad. The risk for low-functioning autism peaked when migration occurred around the 
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time of pregnancy. Different mechanisms can be proposed to explain these results, such as the 
high level of maternal stress or low immunity regarding common infections. 
 
4.2.3 Drugs and toxic exposure 
As previously mentioned, exposure to medication during pregnancy was found to increase 
autism risk in the most recent meta-analyses (Gardener et al, 2009). Prenatal exposure to 
valproate is a recognized risk factor for ASD, especially in the first trimester of pregnancy. It 
was suggested that antidepressant exposure during pregnancy modestly increases the risk of 
ASD, especially in the first semester (Croen et al, 2011). Lastly, exposure in utero to an 
organophosphate insecticide, chlorpyrifos, was found to increase ASD risk and it was 
suggested that synthetic chemicals should be far more explored. 
 
4.3 Gene-environment interaction 
The existence of interactions between genetic background and environmental factors in 
autism was first suggested for perinatal complications. Indeed, in an epidemiological study on 
autism (Glasson et al, 2004) that included a comparison group of siblings, unaffected siblings 
had fewer prenatal and perinatal complications than their affected siblings, but more than 
control subjects. This suggested that individuals with autism may react differently to the same 
environmental stimuli and may have less tolerance to the prenatal experience compared with 
their siblings. Moreover, studies of animal models have suggested that genetic defects in 
synaptic function may alter sensitivity to the environment. Available evidence for the 
contribution of G×E to autism risk comes from animal models. In a first study (Ehninger et a, 
2012), mice haploinsufficient for the TSC2 gene demonstrated a lack of normal social 
approach behavior only when exposed to maternal immune activation. 
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One of the main problems with this kind of study is that power to detect G×E interactions is 
even lower than power to detect genetic or environmental main effects, and the enthusiasm 
for G×E research in other psychiatric disorders has recently been tempered by the absence of 
replication of many positive results (Duncan et al, 2011). Nevertheless, these studies are 
needed since they might help us to understand the inconsistency in results found in classical 
association studies and provide useful hints with regard to prevention. 
 
4.4 The concept of endophenotype in psychiatry 
 
Despite the successful characterization of the nucleotide base-pair order that represents the 
human genome (Venter et al, 2001; Lander et al, 2001), and although a legion of genetic 
linkage and association studies have been done, psychiatry has had little success in 
definitively identifying “culprit” genes or gene regions in the development of diseases 
categorized by using the field’s diagnostic classification schemas (Cowan et al, 2002; 
Cloninger et al, 2002). The reason there is so much difficulty is undoubtedly—in part— that 
psychiatry’s classification systems describe heterogeneous disorders (Chakravarti and Little, 
2003). In addition to the inherent complexity of psychiatric diseases, which have 
multifactorial and polygenic origins, the brain is the most complex of all organs (Gottesman 
and Gould, 2003). 
Individual cells of the brain are quite different from each other in their transcriptomes, 
proteomes, and morphological phenotypes and also in the thousands of connections and 
interactions with other neurons and glia that are critically important to optimal functioning. 
Different cellular experiences are transduced to differences on the biochemical and epigenetic 
levels so that cellular memories regulated by protein modification, morphometric changes, 
and epigenetic influences make the brain unique among organs (Gottesman and Gould, 2003). 
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Furthermore, the brain is subject to complex interactions not just among genes, proteins, cells, 
and circuits of cells but also between individuals and their changing experiences (Kandel, 
1998). Therefore, the phenotypic output from the brain, i.e., behavior, is not simply a sum of 
all its parts. The theory that genes and environment combine to confer susceptibility to the 
development of diseases surfaced in the early half of the last century, but the use of such a 
framework for exploring the etiology of schizophrenia and other psychiatric disorders is more 
recent (Gottesman and Gould, 2003). In their writings summarizing genetic theories in 
schizophrenia 30 years ago, Gottesman and Shields (1972, 1973) described “endophenotypes” 
as internal phenotypes discoverable by a “biochemical test or microscopic examination.” The 
rationale for the use of endophenotypes in exploring disease processes held that if the 
phenotypes associated with a disorder are very specialized and represent relatively 
straightforward and putatively more elementary phenomena (as opposed to behavioural 
macros), the number of genes required to produce variations in these traits may be fewer 
than those involved in producing a psychiatric diagnostic entity. The methods available for 
endophenotype analysis have advanced considerably since 1972; our current armamentarium 
includes neurophysiological, biochemical, endocrinological, neuroanatomical, cognitive, and 
neuropsychological (including configured self-report data) measures (Leboyer et al, 1998). 
Other terms with patently synonymous meaning, such as “intermediate phenotype,” 
“biological marker,” “subclinical trait,” and “vulnerability marker,” have been used 
interchangeably. These terms may not necessarily reflect genetic underpinnings but may 
rather reflect associated findings. In this context, we use the term “biological marker” to 
signify differences that do not have genetic underpinnings and “endophenotype” when certain 
heritability indicators are fulfilled. For example, putative endophenotypes do not necessarily 
reflect genetic effects. Indeed, these biological markers may be environmental, epigenetic, or 
multifactorial in origin. 
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Criteria useful for the identification of markers in psychiatric genetics have been suggested 
(Gershon and Goldin, 1986) and have been adapted to apply to endophenotypes: 
1. The endophenotype is associated with illness in the population. 
2. The endophenotype is heritable. 
3. The endophenotype is primarily state-independent (manifests in an individual whether or 
not illness is active). 
4. Within families, endophenotype and illness co-segregate. 
 
4. 5 The concept of biomarker 
 
A biomarker can be defined as a biological variable significantly associated with the disease of 
interest and measurable directly on a given patient or more often on his/her biological 
specimens/bodily fluids, using sensitive and reliable quantitative procedures. Given the 
phenotypic heterogeneity of ASD and the well-recognized existence of many “autisms”, each 
characterized by specific etio-pathogenic underpinnings (Persico, 2013), investigators are 
now striving to define a panel of autism biomarkers able to: (a) foster earlier and more 
reliable diagnoses, (b) predict developmental trajectories and treatment response, (c) identify 
individuals at high-risk, eventually leading to the establishment of preventive health care 
strategies, (d) contribute to dissect ASD into more discrete clinical entities, and (e) possibly 
even reveal unknown causes or mechanisms of disease (Persico and Napolioni, 2012). 
 
4.6   Biomarkers in ASD 
 
In the last decades several and different biomarkers have been extensively studied in ASD 
subjects: immunological biomarkers such as lymphocytes, cytochines and antibodies; 
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hormonal biomarkes such as oxytocine, melatonin and testosterone; neurotransmitters such 
as serotonin, dopamine and norepinephrine, GABA and glutamate; opioid peptides; oxidative 
stress biomarkers and reduced methylation capacity biomarkers; porfirins; fat acids.  
So, many autism biomarkers have been proposed to date (Ecker et al., 2010; Wang et al., 
2011a,b; Veenstra-VanderWeele and Blakely, 2012), but scientific, ethical, clinical and 
practical issues still pose a major challenge to their use in clinical practice (Walsh et al., 2011). 
The sensitivity and specificity of each single biomarker in complex disorders like autism is 
generally low. The biological complexity of ASD will likely require age- and sex-specific 
panels, each including several biomarkers belonging to different domains (biochemical, brain 
imaging, dysmorphological, electrophysiological, genetic, immunological, etc.) (Persico and 
Napolioni, 2012). 
 
4.7 Conclusion  
 
In conclusion, even if genetics strongly contributes to autism pathogenesis, however, 
heritability estimates above 90% in the early nineties (Steffenburg et al., 1989; Bailey et al., 
1995) have now dropped down to 37%, while the relative weight of shared environmental 
factors has risen to explain as much as 55% of phenotypic variance in a recent twin study 
(Hallmayer et al., 2011). 
So, increasing prevalence rates, decreasing heritability estimates, and the incomplete 
penetrance of mutations and/or CNVs often inherited from either parent or even de novo 
strongly suggest that ASD pathogenesis may be changing over time (Persico and Napolioni, 
2012). The majority of ASD patients are most compatible with a “multiple hit” model, 
encompassing gene–gene and gene–environment interactions, as well as epigenetic 
contributions related to several factors, such as increasing parental age at the time of 
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conception (Persico and Bourgeron, 2006; Leblond et al., 2010; Persico, 2013). Furthermore, 
studies on endophenotypes and biomarkers in autism suggest that ASD should not be viewed 
strictly as a “brain disease”: the pathophysiological abnormalities underlying autism indeed 
are not limited to the central nervous system (CNS), but often involve other systems such as 
the immune and the gastro-intestinal ones (Persico and Napolioni, 2012). 
Several gastrointestinal issues are often noticed by parents in their autistic children, 
including: (a) constipation; (b) diarrhea; (c) abdominal bloating, discomfort, or irritability; (d) 
gastro-esophageal reflux or vomiting; (e) feeding issues or food selectivity (Buie et al., 2010). 
Interestingly, dysregulated innate immune defenses have recently been linked with 
gastrointestinal issues in a subgroup of autistic children who may be especially vulnerable to 
common microbial dysbiosis (Jyonouchi et al., 2011). 
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Chapter 5 
 
The Role of p-Cresol in ASD  
 
5.1 Introduction 
 
5.1.1 ASD and gut flora 
The gut flora is a complex microbial ecosystem that significantly influences human health 
(Holmes et al., 2011; Kinross et al., 2011). Several studies have assessed the fecal flora of 
autistic and control individuals, reporting an overgrowth of potentially pathogenic gut 
microbial species in a sizable subgroup of autistic patients. Some of these bacterial strains are 
known to produce a toxic substance, the p-cresol. Finegold et al. (2002) initially reported an 
excess of Ruminococcus and Clostridium species, including C. difficile, in fecal samples from 
13 ASD patients compared to 8 controls. Parracho et al (2005) found a higher incidence of the 
Clostridium histolyticum group (Clostridium clusters I and II) in the fecal flora of 58 ASD 
children compared to 10 healthy children. 
Adams et al. (2011) found lower levels of Bifidobacteria and higher levels of Lactobacillus 
species in 58 ASD children compared to 39 controls. Children with autism had significantly 
lower levels of total short chain fatty acids. Gastrointestinal symptoms were positively 
correlated with autism severity. Similarly reduced levels of Bifidobacteria were found by 
Wang et al. (2011a,b) in faecal samples obtained from 23 individuals with ASD compared to 9 
controls, while 22 unaffected siblings displayed intermediate levels.  Williams et al. (2011) 
performed ileal biopsies on 15 autistic and 7 control children both with gastrointestinal 
symptoms. Bioptic tissue from ASD children displayed significantly reduced mRNA levels 
encoding for disaccharidases and hexose transporters. In addition, pyrosequencing analysis 
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revealed reduced Bacteroidetes and relatively increased titres of Firmicutes, especially 
Clostridia. Indirect evidence of abnormal gut flora was obtained by Yap et al. (2010), using a 
metabolomic approach based on 1H NMR spectroscopy and pattern recognition methods on 
urine samples of Australian autistic and control individuals. The studies outlined above 
generally provide no behavioural description of their patient sample, make no attempt to 
clinically characterize patients with an abnormal gut microbiome and typically disregard the 
importance of the developmental trajectory of children. Nonetheless, collectively these results 
support the hypothesis that an abnormal gastrointestinal colonization may occur in a 
subgroup of ASD children. Several factors have been proposed as plausible contributors to 
this phenomenon, including hypochlorhydria (i.e., absent or low gastric acid production), 
abnormal gut motility, frequent use of antibiotics, and IgA deficiency. Also inherited or de 
novo genetic/genomic defects could be involved in some cases. In turn, gut bacteria could 
exert pathological actions through the direct or indirect production of systemic toxins and 
neurotoxins, and/or by triggering the production of auto-antibodies eventually leading to 
neuronal damage (Persico and Napolioni, 2012). 
Finally, in addition to abnormal gut colonization, also excessive gut permeability in some 
autistic children has been reported by several (D'Eufemia et al., 1996; De Magistris et al., 
2010), though not all studies (Robertson et al., 2008). In summary, the relatively high 
frequency and variable spectrum of gastrointestinal symptoms reported by many parents of 
autistic children (Buie et al., 2010) could conceivably stem from a complex combination of 
abnormal gut microbiome, excessive intestinal permeability, local immune dysreactivity and 
possibly pleiotropic roles of autism genes in nervous and gut tissue. 
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5.1.2. P-cresol: Physico-chemical properties 
 
P-cresol (4-methylphenol) belongs to the cresol class of organic aromatic compounds, which 
also includes ortho-cresol, meta-phenol, and other mixed formulations. The main physico-
chemical properties of p–cresol are reported in Table 5. Particularly important for 
environmental behavior and ecotoxicity are its octanol–water partition coefficient (log 
Kow=1.94), high vapor pressure, water solubility, and pKa value of 10.26, indicating that at 
environmentally relevant pH values ranging between 5 and 9, p-cresol is largely non-
dissociated in aqueous solution. 
Table 5. Physico-chemical properties of p-cresol (OECD, 2003; from Persico and Napolioni, 
2012) 
 
 
                             
 
5.1.3. Environmental exposure 
Cresols (o-, m-, p-cresol) are produced in nature through the photo-oxidation of toluene in the 
atmosphere. Environmental exposure to p-cresol through inhalation, skin contact, ingestion of 
food and beverages is relatively common (Mandel, 1971; DeBruin, 1976; Roberts et al., 1977). 
The main natural and artificial sources of p-cresol exposure are listed in Table 6. P-cresol is 
readily biodegradable in aerobiosis, while anaerobic degradation plays amarginal role (OECD, 
2003). Another important source of p-cresol exposure in humans is represented by some gut 
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bacteria, able to express synthetic enzymes not present in human cells. Two distinct synthetic 
pathways have been elucidated in gut bacteria: (a) Clostridium difficile, an anaerobic 
bacterium involved in the most severe forms of antibiotic-associated diarrhea occasionally 
leading to pseudo-membranous colitis and even to death, expresses p-hydroxyphenylacetate 
(p-HPA) decarboxylase, able to push the fermentation of tyrosine up to the formation of p-
cresol (Elsden et al., 1976; Selmer and Andrei, 2001) (Fig. 6). Also C. scatologenes and one 
genre of Lactobacillus employ this synthetic pathway (Yokoyama and Carlson, 1981); (b) 
Pseudomonas stutzeri (Cafaro et al., 2005) and Pseudomonas mendocina (Whited and Gibson, 
1991) produce p-cresol from toluene by expressing toluene mono-oxygenase (Fig. 3). The 
former pathway is predicted to be significantly more important than the latter, given the 
much greater availability of L-tyrosine compared to toluene as a substrate in the gut lumen 
and the broader distribution of p-cresol producing clostridial strains. In fact, exposure to 
toluene primarily occurs through breathing and skin contact, whereas oral ingestion can 
occur only through food or water contaminated with this oil derivative. 
 
          Figure 6. Synthesis of p-cresol from tyrosine by gut bacteria expressing pHPA 
decarboxylase   (from Persico and Napolioni, 2012) 
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Table 6. Natural and artificial sources of p-cresol exposure (from Persico and Napolioni, 
2012). 
 
 
 
                         
                               
 
5.1.3. Metabolism and toxicity in animals 
As partially lipophilic compound, p-cresol travels in the blood mostly protein-bound (Bergé-
Lefranc et al., 2010) and hypoalbuminemia can indeed increase free p-cresol plasma levels 
(De Smet et al., 2003). Only 0.5%–1% of total plasma p-cresol is in free form; approximately 
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95% of total plasma p-cresol is metabolized to p-cresylsulfate through O-sulfonation, which 
occurs primarily in colonic epithelial cells and also in the liver; the remaining 3%–4% is 
metabolized to p-cresylglucuronide through glucuronidation, which takes place only in the 
liver (Mandel, 1971; DeBruin, 1976; Ramakrishna et al., 1991). Free plasma p-cresol and its 
conjugation derivatives p-cresylsulfate and p-cresylglucuronide are filtered by the renal 
glomeruli and can be found in the urines of all individuals in small amounts, primarily 
originating from gut bacteria (Bone et al., 1976; Renwick et al., 1988). It is  thus important to 
underscore that total urinary p-cresol, whose measure is reported in most studies, indeed 
represents the sum of p-cresylsulfate, p-cresylglucuronide and free p-cresol, approximately in 
a 95:4:1 ratio. The pivotal role of gut bacteria in synthesizing these urinary compounds is 
underscored by their significant increase with fasting or slow intestinal transit (Kawakami et 
al., 2007), and conversely by their decrease with fiber-rich diets or probiotics (Cummings et 
al., 1979; Kawakami et al., 2005; Nakabayashi et al., 2011). Signs of acute toxicity in animals 
typically include hypoactivity, salivation, tremors and convulsions. The lethal dose 50 (LD50) 
of oral undiluted p-cresol in rats is 207 mg/kg (Andersen, 2006). Clinical signs of toxicity 
following inhalation include irritation of mucous membranes, excitation and convulsions, 
hematuria at high p-cresol concentrations, and death. P-cresol is corrosive to the skin and can 
cause serious eye damage by contact: the LD50 for dermal application of undiluted p-cresol is 
300 mg/kg in rabbits. The “No Observed Adverse Effect Levels” (NOAEL) for p-cresol in mice 
and rats are generally at or above 50 mg/kg/day, depending on oral, respiratory or dermal 
absorption (Andersen, 2006). Fertility is not compromised by p-cresol, which can instead 
cause fetotoxicity in the form of delayed ossification and reduced body weight when 
administered at toxic levels to pregnant rats, but not to rabbits. In vitro, p-cresol does not 
cause gene mutations in bacterial cells and in mammalian cell systems. 
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5.1.4. Acute and chronic toxicity in humans 
Voluntary or accidental intoxication with p-cresol in humans results in irritation of mouth and 
throat, abdominal pain, vomiting, haemolytic anemia, cardiovascular disturbances, renal and 
liver damage, headache, facial paralysis, seizures, coma and death (Wu et al., 1998; Seak et al., 
2010). Also skin contact can be potentially fatal, causing skin corrosion and discoloration, 
gastrointestinal bleeding, and toxic effects on the nervous system, liver and kidneys (Lin and 
Yang, 1992). P-cresol was initially identified as a uremic toxin, but it was later shown that it is 
instead the accumulation of its conjugated derivative p-cresylsulfate that causes many signs 
and symptoms of chronic renal disease (see Section 5 below). Using cellular, animal and 
human protocols, many damaging effects of chronically elevated p-cresol in humans were 
described, but for at least some of them it is not entirely clear whether and to what extent free 
p-cresol or p-cresylsulfate are responsible. These effects include: 
– hepatotoxicity, likely due to inhibition of mitochondrial respiration. This would result from 
the cytochrome P450-mediated oxidation of either the methyl group or the benzene ring of p-
cresol, leading to the formation of two reactive intermediates, a quinone methide and a ortho-
benzoquinone, respectively, able to produce toxic effects by alkylating cellular proteins and 
nucleic acids (Thompson et al., 1996; Kitagawa, 2001; Yan et al., 2005); 
– increased endothelial permeability and cardiovascular disease (Cerini et al., 2004; Meijers et 
al., 2008; Meijers et al., 2009); 
– immunosuppression and increased susceptibility to infections, caused by blunted 
production of reactive oxygen species by granulocytes, diminished release of IL-12 by 
immunostimulated macrophages, and hampered adhesion of monocytes to endothelial cells 
(Vanholder et al., 1995; Dou et al., 2002; De Smet et al., 2003; Faure et al., 2006; Kawakami et 
al., 2009); 
– inhibition of arachidonic acid-induced platelet aggregation (Chang et al., 2011); 
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– growth retardation in weanling pigs (Yokoyama et al., 1982); 
– increased susceptibility to hearing seizures in mice (Yehuda et al., 1994); 
– membrane depolarization through blockade of the delayed-rectifier RCK1 (Kv1.1) 
potassium channel (Elliott and Elliott, 1997), which is widely expressed in the CNS (Beckh and 
Pongs, 1990); 
– increased lipid peroxidation in rat brain (Calderón-Guzmán et al., 2005); 
– decreased Na+-K+ ATPase activity in rat brain (Calderón-Guzmán et al., 2005); 
– inhibition of the conversion of dopamine to noradrenaline (Goodhart et al., 1987); 
– reduced acetaminophen sulfation capacity, due to competition of p-cresol for sulfate 
conjugation (Clayton et al., 2009). 
Many of the effects described using cellular and animal models, such as neuronal 
depolarization, clearly underlie clinically-relevant signs and symptoms of acute intoxication 
or chronic overexposure to p-cresol in humans, including some potentially relevant to ASD. 
 
To begin addressing possible pathophysiological role of the gut in autism we have measured 
urinary levels of p-cresol in 59 non-syndromic autistic children and in 59 tightly age- and sex-
matched controls (Altieri et al, 2011). Clinical and demographic correlates of urinary p-cresol 
levels were assessed. Since p-cresol can also stem from hydrocarbon contamination, the most 
common form being active/passive smoking, urinary amounts of the nicotine metabolite, 
cotinine, were also measured. 
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5.2 Materials and methods 
 
5.2.1 Patients sample and urine collection 
 
Fifty-nine patients fulfilling DSM-IV diagnostic criteria for an Autism Spectrum Disorder were 
recruited in Central and Northern Italy from 5 Italian clinical centers and were screened for 
non-syndromic autism using MRI, EEG, audiometry, urinary aminoacid and organic acid 
measurements, cytogenetic and fragile-X testing. Patients with dysmorphic features were 
excluded even in the absence of detectable cytogenetic alterations. Patients with sporadic 
seizures (i.e., < 1 every 6 months) were included; patients with frequent seizures or focal 
neurological deficits were excluded. Autistic behaviors were assessed using the official Italian 
version of the ADOS and of the ADI-R, as well as the CARS; adaptive functioning was assessed 
using the VABS; I.Q. was determined using either the Griffith Mental Developmental Scales, 
the Coloured Raven Matrices, the Bayley Developmental Scales or the Leiter International 
Performance Scale. Fifty-nine typically developing controls devoid of any overt ASD 
symptomatology were selected on the basis of a tight sex- and age-matching (+ 1 yr) among 
the offspring of clinical/academic personnel.  
Cases and controls were all Caucasian of Italian ethnicity, with mean age (± SEM) of 8.29 ± 
0.56 and 8.46 ± 0.59 years respectively, and M:F ratio of 44:15 for both. All parents gave 
written informed consent for their children, using the consent form approved by the I.R.B. of 
University Campus Bio-Medico (Rome, Italy). 
First-morning urine were collected at home by parents using sterile containers and were 
brought to each clinical centre the same morning in wet ice. Urine samples were then frozen, 
shipped in dry ice and stored at -80°C until analysis.  
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5.2.2 p-Cresol measurement by HPLC 
Urinary p-cresol concentrations were measured by HPLC. Briefly, an aliquote of frozen urines 
was thawed, mixed and 30L were transferred into a tube containing 60L di HCl 6M and 
heated at 90°C for 60 minutes to hydrolyze glucuronide and sulfate conjugates. After cooling, 
p-cresol was extracted with 1 ml of diethyl ether; 300L of the organic phase were then 
transferred into a tube with 20L of NaOH 0.1N, and lyophilized. The residue was dissolved in 
300L of MilliQ H2O/Acetonitrile 5% and 30 μl were injected for HPLC analysis (Dionex 
Ultimate 3000 HPLC system with variable wavelength detector, column Dionex Acclaim120 
C18 5m 120 A° 4,6x150 mm, temperature at 28°C and detection wavelength at 270 nm). The 
mobile phase consisted of A): H2O/Acetonitrile (90/10) /TFA 0,05% and B) Acetonitrile/TFA 
0,05 %. The gradient elution program was: 0-15 minute, 0-50% B; 15-17 minute, 50-100% B; 
17-20 minute 100% B; 20-21 minute 100%-50% B; 21-25 minute 0% B; the flow rate was 
1 ml/min. Spiked samples were run to determine the efficiency of p-cresol recovery. Standard 
solutions at various p-cresol concentrations were made in MilliQ H2O/ Acetonitrile 5%, from a 
stock p-cresol solution (1mg/ml, Sigma-Aldrich).  
 
5.2.3 Cotinine measurements by Elisa 
Urinary cotinine was measured in duplicate using the Cotinine ELISA kit (Calbiotech). 
Smoking status was determined, as previously described: 0-50 ng/ml=non-smoker; 51-170 
ng/ml=light passive smoker;171-550 ng/ml=heavy passive smoker; >550 ng/ml=active 
smoker. 
 
5.2.4 Statistical analysis 
Cases and controls were contrasted using analysis of variance (ANOVA) for paired data, 
Student’s t-test, Fisher’s exact test, or the chi2 statistics; Kendall’s teta statistics was employed 
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for correlation analysis; regression analysis was always performed on the entire sample 
(N=118). Quantitative data are presented as mean + S.E.M. Statistical significance is set at 
P<0.05. 
 
5.3 Results 
 
Urinary p-cresol concentrations were significantly higher among 59 autistic patients 
compared to 59 matched controls (123.5 + 12.8 vs. 91.2 + 8.7 µg/ml, Student-t = 2.207, 116 
df, P<0.05) (Fig. 7).  
 
Figure 7. Urinary p-cresol concentrations (µg/ml) in 59 ASD patients and in 59 controls (data 
are presented as mean + S.E.M. * p < 0.05). 
 
                               
 
This increase was interestingly restricted to ASD patients younger than 8 years of age (134.1 
+ 20.1 vs. 70.3 + 6.7 µg/ml, Student-t = 2.922, 60 df, P=0.005), whereas no difference was 
found between patients and controls aged 8 or older (111.0 + 14.5 vs. 112.7 + 15.5 µg/ml, t= -
0.81, 54 df, P=0.936), nor were there significant age-related changes in urinary p-cresol 
concentrations among controls between 2 and 18 years old (F = 2.0; 6.58 df; p = 0,082) 
(Fig.8).  
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      Figure 8. Urinary p-cresol concentrations by age group, in 59 ASD patients (black bars) and 
in 59 controls (white bars). Data are presented as mean + S.E.M. Numbers inside each 
column represent sample sizes.  
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Before age 8, levels above 150 µg/ml were detected in 9/32 (28.1%) ASD patients vs 0/32 
controls (P=0.002) (Fig. 9), whereas levels above 140 µg/ml were detected in 9/32 (28.1%) 
ASD patients vs 1/32 (3.1%) controls (P=0.0127).  
Urinary p-cresol displayed no correlation with urinary cotinine levels (Kendall’s tau=-0.005 
for the entire sample, -0.035 for ASD patients, and -0.009 for controls, P=0.939, 0.700, and 
0.922, respectively). We found no evidence of active smoking; on average, non-smokers 
displayed higher, and not lower urinary p-cresol levels compared to light passive smokers (4 
ASD patients and 1 control) and heavy passive smokers (2 controls) (108.8 + 8.2 vs 97.7 + 
25.4 vs 48.4 + 35.0 µg/ml, respectively; F=1.385; 2,58 df, P=0.259). Hence elevated p-cresol 
amounts do not stem from active/passive smoking. 
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Figure 9. Urinary p-cresol concentrations in 32 ASD patient-control pairs, up to 7 years or 
younger. The nine patients highlighted by black circles are all above the maximum p-cresol 
concentration recorded in a typically developing child within this same age range (149.8 
µg/ml, as highlighted by the hyphenated line). 
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Urinary p-cresol concentrations were not significantly influenced by geographical region 
(P=0.261), or by sex (P=0.624), whereas significant effects were detected for diagnostic  
status (P=0.001), and for a status x sex interaction (P=0.02). In fact, 15 ASD females displayed 
significantly higher p-cresol amounts compared to 44 ASD males (188.2 + 35.9 vs. 101.5 + 
10.9 µg/ml, respectively; Student t-test=-2.484, 30df, P<0.05), while female and male controls 
did not differ (70.6 + 15.3 vs. 98.2 + 10.6 µg/ml). Among children aged ≤ 7, urinary p-cresol 
concentrations were vastly higher among female autistics compared to female controls (222.2 
+ 53.4 vs. 51.2 + 16.6 µg/ml, respectively; Student t-test=3.590, 12df, P=0.004), whereas 
differences between male autistics and controls do not reach statistical significance (104.7 + 
17.0 vs. 75.1 + 7.2 µg/ml, respectively; Student t-test=1.128, 46df, P=0.265). In numerical 
terms, if urinary p-cresol amounts had been used as a diagnostic marker in our sample, 
(positive when p-cresol > 150 µg/ml) among children aged 7 or younger the test would have 
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been positive in 5/8 (62.5%) ASD females vs. 4/24 (16.7%) ASD males (Fisher’s exact test, 
P<0.05). 
Interestingly, 8 of 9 (88,9%) small children with urinary p-cresol above 150 µg/ml satisfied 
DSM-IV diagnostic criteria for the most severe form of ASD, autistic disorder, compared to 
only 11/23 (47,8%) of the remaining children in the same age interval, who displayed 
significantly higher rates of the less severe form, PDD-NOS (Fischer’s exact test, p<0.05). 
Among children aged 7 or younger, all 15 CARS items measuring clinical severity were 
positively correlated with urinary p-cresol amounts, reaching statistical significance for 
imitation (item no.2: tau: 0.396, p = 0.020, N= 21), use of body (item no.4: tau: 0.330, p = 
0.036), verbal communication (item no.11: tau: 0.387, p = 0.023) and general impression 
(item no.15: tau: 0.534, p = 0.002). Also ADOS, ADI-R and VABS scores displayed correlation 
trends consistent with those found with the CARS, but p-values did not reach statistical 
significance due to low statistical power in our sample. Small children with urinary p-cresol 
above 150 µg/ml, compared to children with normal p-cresol amounts, showed non 
significant trends (p < 0.1) toward more frequent mental retardation [(7/8 (87.5%) vs. 8/17 
(47.1%)], self-injurious behaviours [(4/9 (44.4%) vs. 3/18 (16.7%)], and a history of 
regression [(6/9 (66.7%) vs. 7/23 (30.4%)]. No significant correlation between urinary p-
cresol and behavioural measures were present in ASD children older than 7 years of age. 
Urinary p-cresol levels were not correlated with body mass index in our entire sample (p = 
0.159), nor in females (p = 0.460), or males (p = 0.250) analyzed separately. 
 
5.4       Discussion 
 
The present study demonstrates a significant increase in urinary p-cresol concentrations 
among 59 Italian ASD patients compared to an equal number of age-, sex-, and ethnically-
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matched controls. This increase is present in approximately 30% of autistic children aged 
seven or younger, the majority being girls in our sample. Urinary excretion of p-cresol appears 
to normalize after age 7 (Fig. 8). Importantly, urinary p-cresol does not derive from human 
metabolism: it can either stem from the presence of gut bacteria such as Clostridium difficile or 
Pseudomomas Stutzeri or from contamination with petroleum hydrocarbon mixtures 
containing p-cresol. The most common source of hydrocarbon contamination, active or 
passive smoking, has been excluded as a cause of elevated urinary p-cresol in our sample by 
measuring urinary cotinine, the nicotine metabolite representing the best known marker of 
passive and active smoking. Other source of environmental to petroleum-derived p-cresol 
cannot be ruled out (Bright and Healey, 2003). However, a selective exposure of autistic and 
not of control children appears unlikely. Hence, a more plausible explanation is that the excess 
of urinary p-cresol may be due to an abnormal gut flora, particularly enriched in clostridium 
difficile according to previously published reports (Finegold et al., 2002, 2010; Song et al., 
2004; Parracho et al., 2005). An excess of this microorganism, which catabolizes tyrosine to p-
cresol thanks to a p-hydroxyphenylacetate decarboxylase, would result in increased p-cresol 
formation, followed by absorption of p-cresol through the gut, filtration by the renal 
glomeruli, and excretion through the urines in greater amounts, compared to non-autistic age-
matched children. Based on this hypothesis, the normalization of urinary p-cresol excretion 
around 8 years of age could reflect an ADS-specific variation in gut microbial composition, 
which normally does change with age but not in its clostridial components (Hopkins et al, 
2002). Conceivably an age-dependent maturation of the gut immune system could yield 
greater control over clostridial overgrowth after 7 years of age. Also genetic and hormonal 
liability could play an important role, with female particular prone to developing elevated 
urinary p-cresol levels but normalizing at an age when sex hormone secretion begin to 
increase. Alternatively, or in association with clostridial gut infection, excessive gut 
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permeability could facilitate p-cresol absorption through the gut wall. The existence of a 
“leaky gut” in a subgroup of ASD patients is controversial and deserves further scrutiny 
according to a recent consensus report (Buie et al, 2010). Our results thus spur interest into 
follow-up studies assessing the potential relationship between elevated urinary p-cresol, 
gastrointestinal symptoms, excessive clostridial gut flora, and enhanced intestinal 
permeability in ASD patients. This study present several limitations. First its exploratory 
nature require caution, until our data are independently replicated. Second, the unforeseen 
role played by age actually brings our sample size from 59 down to 32 case-control pairs, 
reducing our power to detect significant differences and hampering attempts to analyze both 
sexes separately. Third, we have no information on dietary habits, which could conceivably 
influence gut microflora for example trough low soluble fiber content and recent fasting, both 
able to increase p-cresol production and/or absorption (Kawakami et al., 2007). We also have 
no information on recent use of antibiotics, which could change gut microflora and give rise to 
environment that favors p-cresol producing bacteria.  
 
5.5 Conclusions  
 
This preliminary study provide initial evidence of excessive urinary p-cresol levels in a sizable 
subgroup of younger and severely affected autistic children, increasing our interest for 
replication in larger and more thoroughly characterized samples and for testing the role of 
this substance as a biomarker of disease in small children which could contribute to estimate 
autism risk, to support clinical diagnoses or to be correlated to particular clinical phenotypes. 
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Chapter 6 
 
P-Cresol and Developmental Trajectories in ASD 
 
6.1 Introduction 
 
A replication study on urinary p-cresol in ASD children is being undertaken on an 
independent sample of ASD children and controls recruited at the Center for Child and 
Adolescent Psychiatry of the Hopital Bretonneau in Tours (France). Preliminary analyses run 
on 34 French children already replicate significantly higher urinary p-cresol levels in 17 ASD 
cases compared to 17 matched controls (P<0.05). This significant increase occurs only in 8 
case-control pairs aged 7 or below (P<0.01), with no significant difference beyond 7 years of 
age. Urinary p-cresol is again significantly correlated with clinical severity, as documented 
using several clinical scales (Antonio Persico, Andrea Urbani, Sonia Cerullo, Catherine 
Barthelemy, Frederique Bonnet-Briault and Gabriele Tripi, unpublished observation, cited in 
Persico and Napolioni, 2012). In addition to measuring total p-cresol, as in our initial study, 
here separately measured its three fractions, namely free p-cresol, p-cresylsulfate and p-
cresylglucuronate. These compounds account for 0.06%, 95.26% and 4.68%, respectively, of 
total urinary p-cresol in controls. Statistically significant elevations in ASD children compared 
to controls were found for urinary p-cresylsulfate and p-cresylglucuronate (P<0.05), whereas 
free p-cresol displays at this stage a non-significant trend (P=0.086). 
Interest into urinary p-cresol and/or its conjugated derivative p-cresylsulfate, is spurred not 
only by their negative effects on multiple biological systems, but also by their potential for 
inclusion into a multi-biomarker diagnostic panel in small autistic children. 
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The currently available evidence summarized in the previous chapter and in the ongoing 
study cited above provides initial support for postnatal exposure to elevated p-cresol and/or 
p-cresylsulfate as a patho-plastic contributor to the severity of behavioural abnormalities and 
cognitive impairment in autistic children. In particular, p-cresol and/or p-cresylsulfate 
seemingly belong to a restricted set of gut- or environmentally-derived compounds 
potentially able to worsen behavioural abnormalities and cognitive impairment in small 
autistic children. Replication studies will also need to determine whether elevated urinary p-
cresol/p-cresylsulfate in ASD is specific to some racial and ethnic groups or represents a 
generalized finding. It will also be important to determine the precise origin of elevated p-
cresol in small autistic children and to define its influence on the spectrum and intensity of 
clinical signs and symptoms of ASD, on developmental trajectories, and on endophenotypic 
sub-groupings of small children with ASD (Persico and Napolioni, 2012). So we have oriented 
our interest to the relationship between p-cresol levels in young children with ASD and their 
developmental trajectories in preschooler age.  
The aims of the present study are: 
1) To check for the significant elevation of urinary p-cresol and of its derivative compounds in 
a novel Italian sample of autistic children aged 7 or below by comparing their levels of urinary 
compounds with those found in previous studies. 
2) To start the enrolment of a sample of subjects so as to measure their urinary p-cresol and 
derivative compounds during the first evaluation (T0) and the follow-up evaluation (T1), in 
order to test whether p-cresol levels recorded at T0 can be regarded as a predictive factor of 
the subsequent outcomes. 
3) Considering the results of our longitudinal study on diagnostic stability (cited in Chapter 
Two) where we have pointed out a possible role of CSS at T0 as a predictive factor of the 
outcome, we are going to test for the correlation between p-cresol levels and CSS at T0 and at 
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T1, and the correlation between p-cresol levels and other clinical parameters and indices 
(cognitive level, adaptive functioning, CARS or others), in order to determine a combination of 
predictive factors in a novel longitudinal sample.  
 
6.2 Materials and methods  
 
6.2.1 Patients sample and urine collection 
We recruited 36 subjects who had been referred to the PDD section of IRCCS Stella Maris 
Institute in Calambrone (Pisa) from May to November 2012. All patients were screened for 
non-syndromic autism using audiometry, urinary amino-acid and organic acid measurements, 
cytogenetic and fragile-X testing. According to the present clinical guidelines, MRI were 
performed on subjects with neurological signs, mental retardation or epilepsy, while EEG 
were performed on subjects who experienced regression or were thought to suffer from 
epilepsy.  
Inclusion criteria: 1) Clinical diagnosis of AD, PDD-NOS or Asperger Disorder according to 
DSM-IV criteria at T0, while the clinical diagnosis at T1 can be AD, PDD-NOS, Asperger 
Disorder, or non spectrum, since we are interested also in children who grow out of autism 
when preschoolers; 2) Aged less than 8 upon recruitment: we have decided to recruit only 
children within the range of age when p-cresol levels were found to be significantly higher 
than in controls in previous studies.  
Exclusion criteria: 1) dysmorphic major features also in absence of detectable cytogenetic 
alterations. 2) Frequent seizures: > 1 every 6 months (while patients with sporadic seizures, 
i.e., < 1 every 6 months or isolated EEG anomalies were included); 3) Focal neurological 
deficits; 4) Chromosomal or genetic alterations; 5) MRI structural alterations. 
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The mean age at the time of recruitment was 4 years and 8 months (56.22 months ± 3.03; 
range 25-94 months). If we consider the distribution of ranges of age in which p-cresol is 
significantly higher than in controls (see chapter 5: 2-4 years; 5-6 years; 7 years) we had: 21 
children recruited at 2-4 years; 12 children recruited at 5-6 years; 3 children recruited at 7 
years.  
Thirty-two out of 36 subjects were males (88.89 %) while only 4 were females (11.11 %), 
with a M:F ratio of 8:1. Therefore, we recruited 24 children at the time of their first evaluation 
(T0) and 12 children at the time of their FU evaluation (T1).  
At the time of recruitment 17 subjects received a clinical diagnosis of AD, 18 subjects received 
a clinical diagnosis of PDD-NOS (hereinafter referred to as ASD), while one child received a 
clinical diagnosis of Non Spectrum, Mental Retardation and Disruptive Disorder (but he was 
recruited because at his first assessment he had received a diagnosis of PDD-NOS and so he 
had grew out of autism at the FU). 
We collected a voluntary written consent by both parents of each child to participate in the 
research project after an informative conversation about the purposes of the study. 
First-morning urine was collected at home by parents using sterile containers, kept in wet ice 
and brought to the clinical centre on the same morning. Urine samples were thus frozen and 
stored at -80°C in the Neurogenetic Laboratory at IRCCS Stella Maris, and shipped off in dry 
ice to the Molecular Psychiatry and Neurogenetic Laboratory University "Campus Bio-Medico" 
of Rome in December 2012.  
 
6.2.2 Clinical assessment 
ADOS (Lord et al. 1999- see description in Chapter 2), revised ADOS algorithms (Gotham et al., 
2007) and Calibrated Severity Scores (CSS; Gotham et al., 2009) generated by the new ADOS 
algorithms were used to evaluate the severity of autistic symptomatology. 
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CARS (Schopler et al. 1988) consists of 15 items intended to measure the presence and 
severity of ASD. The child is rated on each item based on the clinician’s observation of the 
child’s behaviour throughout the evaluation as well as on the parent’s report. CARS includes 
items on socialization, communication, emotional responses, and sensory sensitivities. CARS 
classifies a child as having mild, moderate, or severe autism, or no autism, with a cut-off of 30 
for the presence of autism.  
Vineland Adaptive Behavior Scales (VABS; Sparrow et al. 1984) is a widely used parent 
interview scale that assesses adaptive functioning in the areas of communication, daily living, 
socialization, and motor skills, as well as yielding an adaptive behaviour composite score. 
Griffiths’ Mental Development Scale, Leiter International Performance Scale, and Wechsler 
Preschool and Primary Scale of Intelligence, were used to assess the cognitive levels of 
subjects.  
Since the subjects were assessed with different standardized psychometric tests at T0 
depending on their language level and age, we assessed non-verbal IQ (nv IQ) according to the 
different tests and we consequently organized the results into 2 categories corresponding to 
presence of Mental Retardation (nvIQ < 70) and absence of Mental Retardation (nvIQ ≥ 70). 
As for the children who were not testable with standardized tests (N = 9) we took into 
account their Composite VABS Deviation Quotient Scores and we collocated them either in the 
former category (if composite DQ was <70; N = 8) or in the latter one (if composite DQ was  ≥ 
70; N = 1)  . 
 
Table 7. Demographic and clinical characteristics of the sample 
    N  Mean/median Range 
Age in yrs (mean ± SEM) of the child    36  4.69 ± 0.25 2-7 
Age in yrs (mean ± SEM) of the 
mother at the time of  delivery 
   36  32.58 ± 0.90 24-42 
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Age in yrs (mean ± SEM) of the father 
at the time of  delivery 
   35  36.51 ± 0.94 26-49 
BMI (mean ± SEM)    35  16.42 ± 0.35 13.46-21.97 
        
Median ADOS scores:     29    
1) Language and communication      5.0 2-8 
2) Social interactions      9.0 2-14 
3) Play and imagination      3.0 0-4 
4) Stereotypes      4.0 0-6 
5) CSS      7.0 3-10 
        
Median CARS scores:    36    
1) Social relationship      2.5 1.5-3.5 
2) Imitation      2.25 1.0-4.0 
3) Emotional response      2.5 2.0-4.0 
4) Use of body      2.5 2.0-4.0 
5) Use of objects      3.0 1.5-4.0 
6) Mental and behavioural flexibility      2.5 1.0-3.5 
7) Visual response      2.5 1.5-3.5 
8) Hearing response      2.5 1.5-3.5 
9) Use of senses      2.0 1.5-3.0 
10) Fear and anxiety      2.0 1.5-3.0 
11) Verbal communication      2.75 2.0-4.0 
12) Non verbal communication      2.0 1.5-3.5 
13) Activity level      2.5 1.0-3.0 
14) Cognitive level      2.0 1.5-2.5 
15) General impression      2.5 1.5-3.5 
CARS Total Scores      37.75 24.5-47.0 
        
Median DQ VABS scores    33    
Communication    33  46.0 27.0-118.0 
Daily living skills    33  59.0 27.0-114.0 
Socialization    33  50.0 27.0-108.0 
Motor skills    21  73.0 27.0-119.0 
Composite    33  57.0 55.0-117.0 
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    N  Percent  
Ethnic Group Caucasic   35  97.2 %  
 Mixed    1  2.8 %  
        
Birth order  1   19  52.8 %  
 2   14  38.9 %  
 3   2  5.6 %  
 Dizygotic twin   1  2,7 %  
        
Gender Male    32  88.89 %  
 Female   4  11.1%  
 M/F  ratio   8:1    
        
Family type Simplex   35  97.2%  
 Multiplex   1  2.8%  
        
DSM-IV Diagnosis Autistic Disorder 
(AD) 
  17  47.2 %  
 PDD-NOS (ASD)   18  50 %  
 Non Spectrum  
(ex ASD) 
  1  2.8 %  
Mental Retardation (IQ or DQ < 70) 
(N: 36) 
 ≥ 70  24  66.67 %  
  < 70  12  33.33 %  
 
We collected clinical and anamnestic information through a semi-structured interview 
administered to the parents/caregivers of the children enrolled:  age of child at the time of the 
interview and age of parents at the time of delivery, ethnic group, birth order, anthropometric 
measures such as head circumference, weight, height, BMI (Body Mass Index), developmental 
milestones (age when first words are uttered, age when pointing and gestures are first used), 
sphincter control onset age, dental eruption age, social smile onset age, history of regression, 
self-injurious behaviours, sensitivity to pain; sleep problems, gastrointestinal problems, 
history of recurrent otites, allergic or autoimmune diseases, family history of neurological 
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and/or psychiatric diseases, of recurrent otites, of allergic or autoimmune diseases; length of 
pregnancy, prenatal and perinatal complications, history of recurrent abortions, special diets 
(e.g., gluten–free, casein-free, or both),  antibiotics administration in the 6 months preceding 
the recruitment. Other clinical relevant data were collected during the assessment by either 
Child Psychiatrist or the staff who produce the case history files: hyperactivity, motor and 
vocal stereotyped behaviours, self-injurious behaviours, pathologic EEG patterns, hypotonia, 
congenital anomalies, drug therapy.  
 
6.2.3 Total p-Cresol measurement by HPLC 
Urinary p-cresol concentrations were measured by means of HPLC, as described in Chapter 5.  
 
6.2.4     Statistical analysis  
Statistical analyses were performed with IBM SPSS Statistics 19. 
Correlations between p-cresol levels and test scores (ADOS, CARS, VABS, and IQ scores) were 
checked in the whole sample using both parametric (Pearson correlation) and non parametric 
tests (Kendall’s Tau-B); correlations between p-cresol levels and other clinical variables were 
checked by means of Mann-Whitney Test, Kruskall-Wallis Test and One-Way ANOVA for 
independent samples. 
Subgroups with different developmental profiles were contrasted using Student’s t-test and 
Mann-Whitney test. A Power Analysis was performed with Power.Exe Program. 
Quantitative data were computed as average + S.E.M. Statistical significance was set at P<0.05. 
 
6.3       Results 
The mean value of urinary total p-cresol concentrations in the whole sample was 60.63 + 
10.88 µg/ml (range 2.11-354.97 µg/ml; median: 40.34 µg/ml). 
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Urinary p-cresol levels were not correlated with body mass index in our entire sample (p = 
0.414). Urinary p-cresol concentrations in subjects with a clinical diagnosis of AD did not 
differ significantly (n: 17; 62.65 + 11.79 µg/ml) from subjects with clinical diagnosis of PDD-
NOS (n: 18; 57.98 + 11.33 µg/ml; Pearson correlation: 0.035; p = 0.084; Tau_b Kendall: p = 
0.792), even though we observed the tendency of higher levels of p-cresol to correlate with 
AD clinical diagnosis, and therefore with a more severe symptomatology (see Fig. 10).  
 
Fig. 10 p-cresol levels in subjects with AD and ASD diagnosis. 
 
                     
 
 
In the whole sample, p-cresol levels were not found to be significantly correlated with ADOS 
Total scores (Pearson Correlation, p = 0,874; Kendall Tau_b, p = 0,792), nor with ADOS 
Calibrated Severity Score (Pearson correlation, p = 0,588; Kendal Tau_b, p = 0,390). No 
significant correlation (with partial correlation test) was found between p-cresol levels and 
ADOS Communication scores (p = 0.812), ADOS Interaction scores (p = 0.652), ADOS 
Repetitive/Stereotyped Behaviours Scores (p =  0.835), and ADOS Play (p = 0.238). 
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No significant correlation was found between p-cresol levels and VABS Composite Deviation 
Quotient (Pearson correlation, p = 0,649; Kendall Tau_b, p = 0,212). 
Moreover, p-cresol levels did not show any significant correlation with CARS total scores 
(Pearson correlation, p = 0,496; Kendall Tau_b test, p = 0,230). 
We subsequently performed a non-parametric correlation analysis among total p-cresol levels 
and each of the 15 CARS item scores. We did not find any significant correlation, but the Item 
no. 1 (Social Interaction) and 7 (Visual Response) tended to show a positive correlation with 
p-cresol levels (Item no.1: tau: 0.224 , p = 0.084; Item no 7: tau: 0.231, p = 0.075). 
We did not find any significant correlation between p-cresol total levels and cognitive levels 
(e.g., presence or absence of Mental Retardation, IQ/DQ < 70 or IQ/DQ ≥ 70), nor with 
Pearson correlation (p = 0.864), or with Kendall Tau_b (p = 0.331), or with one-way ANOVA 
(df 2: 33; p = 0.467). In children with IQ < 70 (N = 12) p-cresol levels were 62.30 + 13.05 
µg/ml, while in children with IQ ≥ 70 (N = 23) p-cresol levels were 59.18 + 16.06 µg/ml. 
We checked for correlations between p-cresol urinary concentrations and some of the clinical 
variables and parameters reported in Table 9 by means of One-Way Analysis of Variance, 
Partial Correlations, Mann-Whitney Test for independent samples, and Kruskal-Wallis test for 
independent samples.  
We found no significant difference between p-cresol levels in children with Sleep Problems 
(N: 20; p-cresol 59.52 + 17.86 µg/ml) and in children without Sleep Problems (N: 15; p-cresol 
61.23 + 12.31 µg/ml; ANOVA one-way: df 33; p = 0.942). 
P-cresol levels were not found to be significantly correlated with a history of regression (p = 
0.643), with special skills (p = 0.571), with unusual sensory behaviour/interests (p = 0.594), 
or with motor stereotyped behaviours (p = 0.826). Moreover, no significant difference was 
found between p-cresol levels in children with and without self-injurious behaviours (p = 
0.656); between children with and without gastrointestinal problems (p = 0.666); between 
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children with and without special diets (p = 0.354); between children with and without 
hyperactivity (p = 0.481); between children with and without normal EEG patterns (p = 
0.724). 
 
Table 8. Description of the clinical and anamnestic variables in the wider sample. 
 
Clinical Variables N Mean ± SEM range 
Age at first words (in months) 35 19.14 ± 1.98 7-48 
Age at pointing onset (in months) 31 22.45 ± 2.46 7-60 
Age at gestures onset (in months) 33 20.30 ± 2.54 6-60 
Sphincter control onset age (in 
months) 
21 41.38 ± 2.24 24-60 
Sphincter control not acquired 15   
Social smile onset age (in months) 29 4.03 ± 0.42 2-12 
    
 Description N. % 
Decidual dental eruption age < 4 months 5 13.9 
 4-8 months 23 63.9 
 > 8 months 8 22.2 
History of regression No regression 11 30.6 
 Regression 25 69.4 
Special skills (N: 35) No special skills 15 42.9 
 Special Skills 20 57.1 
Insistence in the sameness (N: 35) No insistence 18 51.4 
 Insistence 17 48.6 
Unusual sensory behaviour/interests No sensory b/i 8 22.2 
 Sensory b/i 28 77.8 
Sensitivity to pain Normal sensitivity 22 61.1 
 Reduced sensitivity 12 33.3 
 Enhanced sensitivity 2 5.6 
Self-injurious behaviours No self-injurious 20 55.6 
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 Self-injurious 16 44.4 
Sleep problems No sleep problems 15 41.7 
 Sleep problems 21 58.3 
Gastrointestinal problems No GI problems 21 58.3 
 GI problems reported 
by parents 
10 27.8 
 GI problems documented 5 13.9 
History of recurrent otites No recurrent otites 24 66.6 
 Recurrent otites reported 
by parents 
6 16.7 
 Recurrent otites documented 6 16.7 
Allergic diseases No allergic diseases 25 69.5 
 Allergic diseases reported 
by parents 
8 22.2 
 Allergic diseases documented 3 8.3 
Autoimmune diseases No Autoimmune diseases 35 97.2 
 Autoimmune diseases 1 2.8 
Other diseases at the onset of autism Other diseases 31 86.1 
 No other diseases 5 13.9 
Family history of neurological  
and/or psychiatric diseases 
Negative 14 38.9 
 Positive 22 61.1 
Family history of recurrent otites Negative 25 69.4 
 Positive 11 30.6 
Family history of allergic diseases Negative 13 36.1 
 Positive 23 63.9 
Family history of autoimmune diseases Negative 29 80.6 
 Positive 7 19.4 
Length of pregnancy 38-42 weeks 31 86.1 
 <38 weeks (pre-term) 4 11.1 
 > 42 weeks (post-term) 1 2.8 
Prenatal complications No complications 24 66.7 
 Complications 12 33.3 
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Perinatal complications No complications 30 83.4 
 Minor complications 3 8.3 
 Major complications 
(with hospitalization) 
3 8.3 
History of recurrent abortions Negative 32 88.9 
 Positive (> 2) 4 11.1 
Special diets No special diets 33 91.7 
 Special diets 
(casein- and gluten-free diet) 
3 8.3 
Food addiction No food addiction 18 50 
 Food addiction 18 50 
Hyperactivity No Hyperactivity 24 66.7 
 Hyperactivity 12 33.3 
Compulsive-ritualistic behaviours No CR behaviours 34 94.4 
 CR behaviours 2 5.6 
Motor stereotyped behaviours No MS behaviours 6 16.7 
 MS behaviours 30 83.3 
Vocal stereotyped behaviours No VS behaviours 13 36.1 
 VS behaviours 23 63.9 
Pathologic EEG patterns (N: 31) 
(5 children did not perform any EEG) 
Normal EEG Patterns 15 48.4 
 Minor EEG abnormalities 
(e.g., not parossistic 
abnormalities) 
4 12.9 
 Epileptiform EEG/Parossistic 
abnormalities 
12 38.7 
Hypotonia (N: 34) No hypotonia 22 64.7 
 Hypotonia 12 35.3 
Congenital anomalies No congenital anomalies 32 88.9 
 Minor congenital anomalies 4 11.1 
 Major congenital anomalies 0 0 
Drug therapy No drug therapy 29 80.6 
 Drug therapy 7 19.4 
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P-cresol levels were not found to be significantly correlated with family history of 
autoimmune disease (p = 0.238), nor with family history of recurrent otites (p = 0.636). 
Interestingly,  p-cresol levels were found to be significantly higher in children without than in 
children with family history of psychiatric and neurologic diseases (without history N: 14; 
91.81 ± 23.54 µg/ml; with history N: 22; 40.79 ± 8.08 µg/ml; Mann-Whitney U Test, p = 0.025; 
Student t-Test, p = 0.022). 
 
Figure 11. p-cresol levels and familiar psychiatric comorbidity. 
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Table 9. Developmental profiles in the sample of 12 children with a FU assessment. 
   
Variables Mean ± SEM Range 
T0 Age (months) 45.0 ± 3.45 20 - 66 
T1 Age (months) 70.5 ± 3.86 48 - 94 
T0-T1 lapse (months) 25.5 ± 3.96 12 - 53 
   
Developmental Profiles N % 
AUT-AUT 5 41.7 
AUT-ASD 3 25 
ASD-ASD 2 16.7 
ASD-AUT 1 8.3 
ASD-NS 1 8.3 
   
Sex N % 
Males 11 91.7 
Females 1 8.3 
 
 
As for possible correlations between p-cresol urinary concentrations and developmental 
profiles, given the very low number of each of the 5 developmental profile subgroups (see 
Table 9), we classified the 12 subjects with a clinical FU into 2 groups:  
Group 1: children who showed an improvement in clinical diagnosis at T1 (profile 2 plus 
profile 5, i.e., AUT-ASD and ASD-NS groups; N = 4). Given the simply exploratory purposes of 
this analysis we added 1 girl to group 1. Regarding this child, we collected data of a 
preliminary FU assessment performed 6 months after T0 (T0: 26 months; T1: 32 months). At 
the FU she had moved from AD to ASD diagnosis (AUT-ASD developmental profile).  
Group 2: children who retained the same diagnosis or received a worse diagnosis at T1 
(profile 1 plus profile 3 plus profile 4, i.e., AUT-AUT, ASD-ASD and ASD-AUT groups; N = 8). 
 92 
We found higher p-cresol levels in Group 2 (106, 52 + 38.05 µg/ml) than in Group 1 (see 
Figure 12; 58.31 + 18.16 µg/ml), even though p-values did not reach statistical significance on 
account of the low statistical power in our sample with both parametric (Student t = 0.947, 11 
df, p = 0.364) and non-parametric analysis (Mann Whitney U Test, p = 0.435).  
We performed one further analysis excluding 1 subject from Group 2, given that his p-cresol 
level differed too much from the average levels in the whole sample (patient nr. P016, p-cresol 
level: 354.97 µg/ml). 
Like with the previous comparison, we found higher p-cresol levels in Group 2 (71.03 + 15.85 
µg/ml) than in Group 1 (58.31 + 18.16 µg/ml), even though p-values did not reach statistical 
significance with both parametric (Student t = 0.525, 10 df, p = 0.611) and non-parametric 
analysis (Mann Whitney U Test, p = 0.639).  
 
Figure 12. p-cresol levels in children who received the same or a worse diagnosis at T1 (group 
2) and in children who received a better diagnosis at T1 (Group 1), respectively. 
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Given the low statistical power of our sample, we subsequently performed a Power Analysis 
with Power.Exe Program in order to estimate the sample size necessary to obtain significant 
difference in p-cresol levels between Group 1 and Group 2. 
Considering the first analysis performed, data included in the Power Analysis were: α: 0.05; β: 
0.020; δ: 48; S: 38; N: 5. The analysis estimated that the sample size of Group 1 should amount 
to 6 subjects. Considering the second analysis performed (the one without the “outlier” 
patient), data included in the Power Analysis were: α: 0.05; β: 0.020; δ: 13; S: 16; N: 5. The 
analysis estimated that the sample size of Group 1 should amount to 15 subjects.   
 
6.4 Discussion 
 
Regarding the urinary p-cresol concentrations in ASD patients younger than 8, the results of 
the present study showed quite different a mean value from that found by Altieri et al., (2011; 
60.25 + 4.12 µg/ml and 134.1 + 20.1 µg/ml, respectively). On the other hand, the mean value 
of urinary p-cresol concentrations in ASD patients younger than 8 in our study was similar to 
that found in the replication study that is being undertaken on an independent sample of ASD 
children and controls recruited at the Center for Child and Adolescent Psychiatry of the 
Hopital Bretonneau in Tours (France); this study (Persico et al., unpublished observation) has 
already been cited in the introduction as well as in Persico and Napolioni (2012).  
Such differences in total urinary p-cresol levels observed in different independent samples 
may arguably be explained considering the factors which may account for the elevation of 
urinary p-cresol levels either on its own or as components of complex pathways. Different 
mechanisms may in fact account for contrasting patterns of p-cresol levels in different and 
independent subgroups of ASD children, by either complementing or contrasting each other in 
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the same child, so as to determine the levels assessed in the present study. As pointed out by 
Persico and Napolioni (2012), among these factors one should consider:  
1) environmental exposure: for example, low-functioning ASD children are likely to pull 
objects painted with cresol-containing gloss to their mouth; “picky eaters” are likely to absorb 
greater amounts of such compound when selecting cresol-enriched foods; some families may 
be administering cresol-enriched antioxidants to their autistic children; 
2) gut infection with cresol-producing bacterial strains: as discussed in Chapter 5, this may 
result in the enhanced synthesis of p-cresol from tyrosine in the gut lumen, absorption 
through the gut wall and urinary excretion of greater amounts of the compound. An abnormal 
gut microbiome may represent a spontaneous ASD-related event in some children and follow 
frequent antibiotic treatments in others;  
3) greater amounts of endogenous proteins in the cecum: such amounts were found to boost 
p-cresol production, absorption, and urinary excretion rates. Several factors can influence the 
concentration of endogenous proteins in the cecal lumen, including: (a) slow intestinal transit 
time (i.e., chronic constipation or fasting); (b) greater gut epithelium turnover rates; (c) 
chronically elevated dietary introduction of tyrosine, taken up into enterocytes and 
subsequently incorporated into cellular proteins; (d) vastly excessive dietary protein intake 
(total proteins or tyrosine-enriched, through milk and its derivatives, soy products, fish, 
chicken, etc.); (e) pharmacological inhibition of gastric acid secretion;  
4) excessive intestinal permeability (the “leaky gut”), which was previously described in a 
consistent subgroup of ASD children (D'Eufemia et al., 1996; De Magistris et al., 2010), may 
also facilitate p-cresol absorption. In turn, excessive p-cresol production and absorption may 
conceivably alter permeability either directly or through inflammatory mechanisms. 
Current studies are aiming to determine which routes are involved in the increase of urinary 
p-cresol excretion in young autistic children. Urinary p-cresol measures were not found to 
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correlate with cecal and faecal p-cresol levels, likely due to inter-individual variability in liver 
metabolic rates (Birkett et al., 1995), whereas urinary p-cresol does, however, parallel plasma 
p-cresol levels, which are toxicologically active over the CNS and other peripheral tissues 
(Birkett et al., 1995). 
Moreover, studies performed in specific cellular and animal models, as well as prospective 
follow-up studies involving baby siblings (i.e., “high-risk” neonates born to parents with one 
grown-up child already diagnosed with ASD) may help determine whether early prenatal 
exposure to environment-derived or maternal gut-derived p-cresol provide pathogenic 
contributions, thus significantly increasing the risk of ASD in the offspring (Persico and 
Napolioni, 2012). 
The present study did not replicate the results of the previous study by Altieri et al. (2011) 
which reported correlation between p-cresol levels and more severe clinical diagnosis, more 
severe autistic symptomatology and female sex. However, we found a tendency of higher 
levels of p-cresol to correlate with AD clinical diagnosis and with higher CARS scores in Item 1 
(Social Interaction) and in Item 7 (Visual Response). Moreover, we found a tendency of higher 
levels of p-cresol to correlate with Mental Retardation. 
Besides, our sample was less numerous and p-cresol mean level was found to be lower than 
those recorded in Altieri’s study. Therefore, should we recruit a wider sample, the statistical 
power of our study may increase and this tendency may reach a statistical significance.  
In our sample p-cresol levels were found to be higher in children without than in children 
with a family history of psychiatric and neurologic diseases. Even though gene-environment 
interactions in autism are very complex and only partially explained, this finding requires 
further investigation. In fact, the correlation between higher p-cresol levels and the absence of 
previous psychiatric and neurologic diseases in the family history may be accounted for by a 
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lower dose of genetic liability and/or a greater pathogenic role of environmental factors such 
as the p-cresol itself.  
As for the hypothesis that p-cresol levels could be regarded as a predictive factor of the 
different developmental outcomes, the present study showed higher p-cresol levels in the 
group of children who either retained the same diagnosis or received a worse diagnosis at T1 
than in the group of children who showed an improvement in clinical diagnosis at T1. Even 
though we could not reach statistical significance, these results were promising in that the 
Power Analysis estimated that the recruitment of 15 subjects for each group (10 further 
subjects in Group 1 -ASD-NS and AUT-ASD- and 8 further subjects in Group 2 – AUT-AUT, 
ASD-AUT and ASD-ASD) would allow for statistical significance. Considering the sample of 24 
children we had already recruited at their first assessment, we can perform a FU assessment 
of these same subjects in about few months, so that we would reasonably obtain further 
interesting information about the role of p-cresol as a predictor of the outcome.  
 
6.5       Conclusions and future perspectives 
 
The results of this study suggest that we should continue our research in order to define 
developmental profiles and clinical phenotypes more accurately and accordingly correlate 
them to p-cresol levels in a wider sample, thus obtaining higher statistical power.  
According to the new DSM 5 classification of ASD, our future research should rely on the 
definition of developmental trajectories no longer based on a categorical approach but rather 
on a dimensional one which takes into account clinical specifiers such as language level, 
cognitive level, and autism severity.  
Besides, our results did not only confirm the great complexity and heterogeneity of clinical 
and functional phenotypes inside the wide autism spectrum, but also the complex interactions 
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among them and the underlying neurobiological mechanisms. Moreover, we should collect 
further and more precise information about gastrointestinal symptoms and gastrointestinal 
function in order to better define the possible correlations between them and p-cresol levels. 
With future investigation on the “gene-environment-phenotype interactions” in mind, we also 
collected a second urine sample from each child during the recruitment. These urinary 
samples were frozen and stored at -80°C in the Neurogenetic Laboratory at IRCCS Stella Maris 
so that we will be able to perform DNA extraction from urogenital system epithelial cells and 
study genetic patterns potentially correlated to autism in the same subjects whose p-cresol 
levels we had determined.  
Finally, in such a complex framework we recommend that future research in autism be led by 
means of thorough and punctual assessments of all the clinical variables that contribute to the 
complexity of this puzzling disease, and that these variables be punctually correlated with all 
the neurobiological findings. 
 
 98 
 
 99 
Selected references 
 
1. Altieri, L.  Neri, C. , Sacco, R., Curatolo, P., Benvenuto, A. Muratori, F., Santocchi, E., 
Bravaccio C., Lenti, C., Saccani, M., Rigardetto, R., Gandione, M., Urbani, A., Persico A.M., 
Urinary p-cresol is elevated in small children with severe autism spectrum disorder. 
Biomarkers 2011 May;16(3): 252-60. 
2. Muratori F., Calderoni S,  Apicella F., Filippi T., Santocchi E.,  Calugi S.,  Cosenza A., 
Tancredi R, Narzisi A. Tracing back to the onset of abnormal head circunference 
growth in Italian children with autism spectrum disorder. Research in Autism Spectrum 
Disorders, 2012, 6, 442-449. 
3. Muratori F., Narzisi A., Calderoni S., Calugi S., Apicella F., Santocchi E., Tancredi., 
(2010) Head Circumference Growth and Autism, 57th Annual Meeting of the American 
Academy of Child and Adolescent Psychiatry (AACAP), New York (USA) 25-31 Ottobre, 
published in Abstract Book. 
4. Muratori F., Narzisi A., Tancredi R, Cosenza A.,Calugi S., Saviozzi I., Santocchi E., 
Calderoni S. The CBCL 1.5-5 and the identification of preschoolers with autism in Italy. 
Epidemiology and Psychiatric Sciences, 2011 Dec; 20(4): 329-38.  
5. Prandini P., Pasquali A., Malerba G., Marostica A., Zusi C., Xumerle L., Muglia P., Da Ros 
L., Trabetti E., Pignatti P. & The Italian Autism Network (ITAN). The association of 
rs4307059 and rs35678 markers with Autism Spectrum Disorders is replicated in 
Italian families. Psychiatric Genetics, 2012, 22(4):177-81.  
6. Prosperi M., Apicella F., Igliozzi R., Narzisi A., Santocchi E., Tancredi R., Muratori F. 
Evoluzione dell’autismo in età prescolare: stabilità diagnostica e trattamento a 24 mesi 
dalla diagnosi. XXV congresso Nazionale Sinpia, Pisa, 11-14 maggio 2011, published in 
Abstract Book. 
 100 
7. Prosperi M, Santocchi E., Tancredi R., Fantozzi P., Muratori F. “Evoluzione dell’autismo 
diagnosticato nei primi quattro anni di vita”. Autismo e disturbi dello sviluppo, 2013, 11 
(1): 73-86.  
8. Santocchi E., Muratori F. L’autismo nel DSM-5. Infanzia e Adolescenza, 2012, 
11(3):158-174 
9. Santocchi E., Prosperi M., Tancredi R., Muratori F. “Diagnostic stability of autism in 
preschool age”. Poster presented at IACAPAP 2012, 20th World Congress, Paris, July 
21-25 2012. Published in : Neuropsychiatrie de l’Enfance et de l’Adolescence, volume 
60, issue 5, Supplement, July 2012, page S198.  
10. Santocchi E., Tancredi R., Narzisi A., Igliozzi R., Apicella F., Calderoni S., Ceschia R., 
Calugi S., Muratori. F. (2010), Stabilità della diagnosi di autismo in età prescolare, 
Psichiatria dell’infanzia e dell’adolescenza, vol. 77, numero 3, Settembre-Dicembre 
2010, 489-501. 
11. Santocchi E., Prosperi M., Tancredi R., Baldini S., Igliozzi R, Apicella F., Narzisi A., 
Muratori F. (2013). Diagnostic Stability and Developmental Profiles of Autism in 
Preschool Age. Poster presented at IMFAR 2013, 12th Annual Meeting, Donostia (San 
Sebastian), May 2-4 2013. Published in: Abstract Book. 
 101 
References 
 
1. Abrahams, BS.; Geschwind, DH. Encyclopedia of Genetics, Genomics, Proteomics and          
Bioinformatics. Dunn, MJ.; Jorde, LB.; Little, PFR.; Subramaniam, S., editors. John Wiley 
&  Sons; 2005. p. p1-12.section 1.5. 
2. Abrahams and Geschwind, Advances in autism genetics: on the threshold of a new 
neurobiology, Nat Rev Genet, 2008 May; 9 (5); 341-355. 
3. Adams JB, Johansen LJ, Powell LD, Quig D, Rubin RA. Gastrointestinal flora and 
gastrointestinal status in children with autism—comparisons to typical children and 
correlation with autism severity. BMC Gastroenterol 2011;11:22. 
4. Aerts S, et al. Gene prioritization through genomic data fusion. Nature Biotechnol 
2006;24:537–544. 
5. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental 
disorders (4th ed.). Washington, DC: American Psychiatric Association. 
6. American Psychiatric Association (2000), Diagnostic and statistical manual of mental 
disorders (4th edn, revised), Washington, DC:  American Psychiatric Association. 
7. American Psychiatry Association (2013). DSM-5 development. Available from: 
http://www.dsm5.org [last accessed 28 August 2012]. 
8. Andersen A. Final report on the safety assessment of sodium p-chloro-m-cresol, p-
chloro-m-cresol, chlorothymol, mixed cresols, m-cresol, o-cresol, p-cresol, isopropyl 
cresols, thymol, o-cymen-5-ol, and carvacrol. Int J Toxicol 2006;25(Suppl. 1):29-127. 
9. Andreasen NC: Schizophrenia: the fundamental questions. Brain Res Brain Res Rev 
2000; 31:106–112. 
10. Anney R, Klei L, Pinto D, Regan R, Conroy J, Magalhaes TR, et al. (2010). A genome-wide 
scan for common alleles affecting risk for autism. Hum Mol Gen, 19; 4072-4082.  
 102 
11. Ashwood P, Corbett BA, Kantor A, Schulman H, Van de Water J, Amaral DG. In search of 
cellular immunophenotypes in the blood of children with autism. PLoS One. 
2011;6:e19299. 
12. Autism and Developmental Disabilities Monitoring Network 2006 Principal 
Investigators. (2009). Prevalence of autism spectrum disorders—Autism and 
developmental disabilities monitoring network, United States, 2006. Morbidity and 
Mortality Weekly Report, 58(SS-10), 1–21. 
13. Badner JA, Gershon ES. Regional meta-analysis of published data supports linkage of 
autism with markers on chromosome 7. Mol. Psychiatry 2002;7:56–66. 
14. Bailey A, et al. Autism as a strongly genetic disorder: evidence from a British twin 
study. Psychol. Med 1995;25:63–77. 
15. Bailey, A., Phillips, W., Rutter, M., 1996. Autism: towards an integration of clinical, 
genetic, neuropsychological, and neurobiological perspectives. J. Child Psychol. 
Psychiatry 37, 89–126. 
16. Baron CA, et al. Genomic and functional profiling of duplicated chromosome 15 cell 
lines reveal regulatory alterations in UBE3A-associated ubiquitin-proteasome pathway 
processes. Hum. Mol.Genet 2006;15:853–869. 
17. Beckh S, Pongs O. Members of the RCK potassium channel family are differentially 
expressed in the rat nervous system. EMBO J 1990;9:777–82. 
18. Benayed R, Gharani N, Rossman I, Mancuso V, Lazar G, Kamdar S, Bruse SE, Tischfield S, 
Smith BJ, Zimmerman RA, Dicicco-Bloom E, Brzustowicz LM, Millonig JH. (2005). 
Support for the homeobox transcription factor gene ENGRAILED 2 as an autism 
spectrum disorder susceptibility locus. Am J Hum Genet. 2005 Nov;77(5):851-68. Epub 
2005 Oct 5. 
19. Bergé-Lefranc D, Chaspoul F, Calaf R, Charpiot P, Brunet P, Gallice P. Binding of p-
 103 
cresylsulfate and p-cresol to human serum albumin studied by microcalorimetry. J 
Phys Chem B 2010;114:1661–5. 
20. de Bildt A, Oosterling IJ, van Lang ND, Sytema S, Minderaa RB, van Engeland H, Roos S, 
Buitelaar JK, van der Gaag RG, de Jonge MV (2011), Standardized ADOS scores: 
Measuring severity of autism spectrum disorders in a Dutch sample. Journal of Autism 
and Developmental Disorders, 41(3), 311–319. 
21. Birkett A.M., Jones G.P., Muir J.G. (1995), Simple high-performance liquid 
chromatographic analysis of phenol and p-cresol in urine and feces Journal of 
Chromatography B, Biomedical Sciences and Applications, 674, 187-91.  
22. Bishop D (2011), How common is autism? Notes and Theories blog on guardian.co.uk. 
Available from: http://www.guardian.co.uk/science/blog/2011/jun/07/ how-
common-autism-diagnosis. 
23. Bishop DV (1989), Autism, Asperger’s syndrome and semantic- pragmatic disorder: 
Where are the boundaries? British Journal of Disorders of  Communication, 24(2), 107–
121. 
24. Bishop DV, et al. Using self-report to identify the broad phenotype in parents of 
children with autistic spectrum disorders: a study using the Autism-Spectrum 
Quotient. J. Child Psychol. Psychiatry 2004;45:1431–1436.  
25. Bittel DC, Kibiryeva N, Butler MG. Whole genome microarray analysis of gene 
expression in subjects with fragile X syndrome. Genet. Med 2007;9:464–472. 
26. Blomquist HK, et al. Frequency of the fragile X syndrome in infantile autism. A Swedish 
multicenter study. Clin. Genet 1985;27:113–117.  
27. Bolton P, et al. A case–control family history study of autism. J. Child Psychol. 
Psychiatry 1994;35:877–900. 
28. Bone E, Tamm A, Hill M. The production of urinary phenols by gut bacteria and their 
 104 
possible role in the causation of large bowler cancer. Am J Clin Nutr 1976;29:1448–54. 
29. Boucard AA, Chubykin AA, Comoletti D, Taylor P, Sudhof TC. A splice code for trans-
synaptic cell adhesion mediated by binding of neuroligin 1 to alpha- and beta-
neurexins. Neuron 2005;48:229– 236. 
30. Bright DA, Healey N. (2003). Contaminant risks from biosolids land application: 
contemporary organic contaminant levels in digestive sewage sludge from five 
treatment plants in Greater Vancouver, British Columbia. Envir Pollut, 126: 39-49. 
31. Bristol, M. M., Cohen, D. J., Costello, E. J., Denckla, M., Eckberg, T. J., Kallen, R., et al. 
(1996). State of the science in autism: Report to the National Institutes of Health. 
Journal of Autism and Developmental Disorders, 26(2), 121–154. 
32. Buie T, Campbell DB, Fuchs III GJ, Furuta GT, Levy J, Vandewater J, et al. Evaluation, 
diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a 
consensus report. Pediatrics 2010;125:1-18. 
33. Buxbaum JD, et al. Evidence for a susceptibility gene for autism on chromosome 2 and 
for genetic heterogeneity. Am. J. Hum. Genet 2001;68:1514–1520. 
34. Cafaro V, Notomista E, Capasso P, Di Donato A. Mutation of glutamic acid 103 of 
toluene o-xylene monooxygenase as a means to control the catabolic efficiency of a 
recombinant upper pathway for degradation of methylated aromatic compunds. Appl 
Environ Microbiol 2005;71:4744–50. 
35. Calderón-Guzmán D, Hernández-Islas JL, Espítia Vázquez IR, Barragán-Mejía G, 
Hernández-García E, Del Angel DS, et al. Effect of toluene and cresols on Na+, K+-
ATPase, and serotonin in rat brain. Regul Toxicol Pharmacol 2005;41:1–5. 
36. Cantor RM, et al. Replication of autism linkage: fine-mapping peak at 17q21. Am. J. 
Hum. Genet 2005;76:1050–1056. 
37. Carayol J, Letexier M, Tores F, Rousseau F, Sacco R, Persico AM et al, (2009). 
 105 
Association Study of a Linkage Region on Chromosome 3P25 in 816 Families Shows 
Strong Evidence for association of ATP2B2 with Autism and Language Delay 
[http://imfar.confex.com/imfar/2009/webprogram/Paper4258.html].  
38. Carayol J, Sacco R, Tores F, Rousseau F, Lewin P, Hager J, Persico AM. (2011). 
Converging evidence for an association of ATP2B2 allelic variants with autism in male 
subjects. Biol Psychiatry. Nov 1;70(9):880-7. 
39. Carayol J, Schellenberg GD, Tores F, Hager J, Ziegler A, Dawson G. (2010). Assessing the 
impact of a combined analysis of four common low-risk genetic variants on autism risk. 
Mol Autism. 2010 Feb 22;1(1):4. 
40. Cederlund, M., Hagberg, B., Billstedt, E., Gillberg, I. C., & Gillberg, C. (2008). Asperger’s 
syndrome and autism: A comparative longitudinal follow-up study more than four 
years after original diagnosis. Journal of Autism and Developmental Disorders, 38, 72–
85. 
41. Cerini C, Dou L, Anfosso F, Sabatier F, Moal V, Glorieux G, et al. P-cresol, a uremic 
retention solute, alters the endothelial barrier function in vitro. Thromb Haemost 
2004;92:140–50. 
42. Chakravarti A, Little P: Nature, nurture and human disease. Nature 2003; 421:412–
414. 
Chang MC, Wang TM, Yeung SY, Jeng PY, Liao CH, Lin TY, et al. Antiplatelet effect by p-
cresol, a uremic and environmental toxicant, is related to inhibition of reactive oxygen 
species, ERK/p38 signaling and thromboxane A2 production. Atherosclerosis 
2011;219:559–65. 
43. Charman T., Baird, G. (2002), Practitioner Review: Diagnosis of autism spectrum 
disorder in 2- and 3-year-old children, Journal of Child Psychology and Psychiatry, 43, 3: 
289-305. 
 106 
44. Charman T., Taylor E., Drew A., Cockerill H., Brown J.A., Baird G. (2005), Outcome at 7 
years of children diagnosed with autism at age 2: predictive validity of assessment 
conducted at 2 and 3 years of age and pattern of symptom change over time. Journal of 
Child Psychology and Psychiatry, 46,5: 500-513. 
45. Chaste P, Leboyer M (2012). Autism risk factors: genes, environment, and gene-
environment interactions. Dialogues in Clinical Neuroscience, 14, 3: 281-292.  
46. Chawarska K, Klin A, Paul R, Macari S, Volkmar F. A prospective study of toddlers with 
ASD: short-term diagnostic and cognitive outcomes. J Child Psychol Psychiatry. 
2009;50(10):1235-45. 
47. Chawarska K, Klin A, Paul R, Volkmar F. Autism spectrum disorder in the second year: 
stability and change in syndrome expression. J Child Psychol Psychiatry. 
2007;48(2):128-38. 
48. Clayton TA, Baker D, Lindon JC, Everett JR, Nicholson JK. Pharmacometabonomic 
identification of a significant host–microbiome metabolic interaction affecting human 
drug metabolism. Proc Natl Acad Sci U S A 2009;106:14728–33. 
49. Cloninger CR: The discovery of susceptibility genes for mental disorders. Proc Natl 
Acad Sci USA 2002; 99:13365–13367 Andreasen NC: Understanding the causes of 
schizophrenia (letter). N Engl J Med 1999; 340:645–647. 
50. Cordell HJ (2004). Properties of case/pseudocontrol analysis in genetic association 
studies: effects of recombination, ascertainment and multiple affected offspring. Genet 
Epidemiol, 26: 186-205.  
51. Coutanche, M.N., Thompson-Schill, S.L., & Schultz, R.T. (2011). Multi-voxel pattern 
analysis of fMRI data predicts clinical symptom severity. Neuroimage, 57(1), 113–123. 
52. Cowan WM, Kopnisky KL, Hyman SE: The human genome project and its impact on 
psychiatry. Annu Rev Neurosci 2002; 25:1–50. 
 107 
53. Cox A, Klein K, Charman T, Baird G, Baron-Cohen S, Swettenham J, et al. Autism 
spectrum disorders at 20 and 42 months of age: stability of clinical and ADI-R 
diagnosis. J Child Psychol Psychiatry. 1999;40(5):719-32. 
54. Croen LA, Grether JK, Yoshida CK, Odouli R, Hendrick V. Antidepressant use during 
pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry. 
2011;68:1104-1112. 
55. Cummings JH, Hill MJ, Bone ES, Branch WJ, Jenkins DJ. The effect of meat protein and 
dietary fiber on colonic function and metabolism. II. Bacterial metabolites in feces and 
urine. Am J Clin Nutr 1979;32:2094–101. 
56. Daniels AM, Rosenberg RE, Law JK, Lord C, Kaufmann WE, Law PA. 2011. Stability of 
initial autism spectrum disorder diagnoses in community settings. J Autism Dev Disord 
41:110–121. 
57. Darrou C, Pry R, Pernon E, Michelon C, Aussilloux C, Baghdadli A. 2010. Outcome of 
young children with autism. Autism 14:663–677. 
58. DeBruin A. Metabolism of occupational agents. In: De Bruin A, editor. Biochemical 
toxicology of environmental agents. Amsterdam: Elsevier/North-Holland Biomedical 
Press; 1976. p. 87-170. 
59. De Magistris L, Familiari V, Pascotto A, Sapone A, Frolli A, Iardino P, et al. Alterations of 
the intestinal barrier in patients with autism spectrum disorders and in their first-
degree relatives. J Pediatr Gastroenterol Nutr 2010;51:418–24. 
60. De Smet R, Van Kaer J, Van Vlem B, De Cubber A, Brunet P, Lameire N, et al. Toxicity of 
freep-Cresol: a prospective and cross-sectional analysis. Clin Chem 2003;49:470–8. 
61. D'Eufemia P, Celli M, Finocchiaro R, Pacifico L, Viozzi L, Zaccagnini M, et al. Abnormal 
intestinal permeability in children with autism. Acta Paediatr 1996;85:1076–9. 
62. Dou L, Cerini C, Brunet P, Guilianelli C, Moal V, Grau G, et al. P-cresol, a uremic toxin, 
 108 
decreases endothelial cell response to inflammatory cytokines. Kidney Int 2002;62: 
1999–2009. 
63. Duncan LE, Keller MC. A critical review of the first 10 years of candidate gene-by-
environment interaction research in psychiatry. Am J Psychiatry. 2011;168:1041-1049. 
64. Eaves LC, Ho HH. The very early identification of autism: outcome to age 4 1/2-5. J 
Autism Dev Disord. 2004;34(4):367-78. 
65. Ecker C, Marquand A, Mourão-Miranda J, Johnston P, Daly EM, Brammer MJ, et al. 
Describing the brain in autism in five dimensions—magnetic resonance imaging-
assisted diagnosis of autism spectrum disorder using a multiparameter classification 
approach. J Neurosci 2010;30:10612–23. 
66. Ehninger D, Sano Y, de Vries PJ, et al. Gestational immune activation and Tsc2 
haploinsufficiency cooperate to disrupt fetal survival and may perturb social behavior 
in adult mice. Mol Psychiatry. 2012;17:62-70. 
67. Elliott AA, Elliott JR. Voltage-dependent inhibition of RCK1 K+ channels by phenol, p-
cresol, and benzyl alcohol. Mol Pharmacol 1997;51:475–83. 
68. Elsden SR, Hilton MG, Waller JM. The end products of the metabolism of aromatic 
amino acids by Clostridia. Arch Microbiol 1976;107:283–8. 
69. Fein, D, Barton, M, Eigsti, I, Kelley, E, Naigles, L, Schultz, RT, Stevens, M, Helt, M, 
Orinstein, A,  Rosenthal, M, Troyb, E, and Tyson K. (2013). Optimal outcome in 
individuals with a history of autism. Journal of Child Psychology and Psychiatry 54:2; 
195–205. 
70. Fernandez-Gonzalez R, Moreira P, Bilbao A, et al. Long-term effect of in vitro culture of 
mouse embryos with serum on mRNA expression of imprinting genes, development, 
and behavior. Proc Natl Acad Sci U S A. 2004;101:5880-5885. 
71. Finegold SM, Molitoris D, Song Y, Liu C, Vaisanem ML, Bolte E, et al. Gastrointestinal 
 109 
microflora studies in late-onset autism. Clin Infect Dis 2002;35:6-16. 
72. Finegold SM, Dowd SE, Gontcharova V, Liu C, Henley KE, Wolcott RD, et al. 
Pyrosequencing study of fecal microflora of autistic and control children. Anaerobe 
2010;16:444–53. 
73. Fombonne, E., (2003). Epidemiological surveys of autism and other pervasive 
developmental disorders: an update. J. Autism Dev. Disord. 33, 365-382. 
74. Fombonne E. Epidemiology of pervasive developmental disorders. Pediatr Res. 
2009;65:591-598. 
75. Fountain C, Winter AS, Bearman PS (2012). Six Developmental Trajectories 
Characterize Children with Autism, Pediatrics, 129, 5: 1112-1120. 
76. Gardener H, Spiegelman D, Buka SL. Prenatal risk factors for autism: comprehensive 
meta-analysis. Br J Psychiatry. 2009;195:7-14. 
77. Gardener H, Spiegelman D, Buka SL. Perinatal and neonatal risk factors for autism: a 
comprehensive meta-analysis. Pediatrics. 2011;128:344-355. 
78. Gershon ES, Goldin LR: Clinical methods in psychiatric genetics, I: robustness of genetic 
marker investigative strategies. Acta Psychiatr Scand 1986; 74:113–118. 
79. Geschwind DH, Levitt P. Autism spectrum disorders: developmental disconnection 
syndromes. Curr. Opin. Neurobiol 2007;17:103–111.  
80. Gharani N, Benayed R, Mancuso V, Brzustowicz LM, Millonig JH. (2004). Association of 
the homeobox transcription factor, ENGRAILED 2, 3, with autism spectrum disorder. 
Mol Psychiatry. 2004 May;9(5):474-84. 
81. Gillberg C, Ehlers S, Schaumann H, Jakobsson G, Dahlgren SO, Lindblom R, et al. Autism 
under age 3 years: a clinical study of 28 cases referred for autistic symptoms in infancy. 
J Child Psychol Psychiatry. 1990;31(6):921-34. 
82. Gilliam. (1995). Gilliam autism rating scale. Austin, TX: Pro-ed. 
 110 
83. Glasson EJ, Bower C, Petterson B, de Klerk N, Chaney G, Hallmayer JF. Perinatal factors 
and the development of autism: a population study. Arch Gen Psychiatry. 2004;61:618-
627. 
84. Goodhart PJ, DeWolf WE, Kruse LI. Mechanism-based inactivation of dopamine beta-
hydroxylase by p-cresol and related alkylphenols. Biochemistry 1987;26: 2576–83. 
85. Gotham K, Pickles A, Lord C (2009), Standardizing ADOS scores for a measure of 
severity in autism spectrum disorders. Journal of Autism and Developmental Disorders, 
39(5), 693–705. 
86. Gotham K, Risi S, Pickles A, Lord C (2007), The Autism Diagnostic Observation 
Schedule: Revised algorithms for improved diagnostic validity. Journal of Autism and 
Developmental Disorders, 37(4), 613–627. 
87. Gottesman I.I., Gould, T.D. The Endophenotype Concept in Psychiatry: Etymology and 
Strategic Intentions. Am J Psychiatry 2003; 160:636–645. 
88. Gottesman II, Moldin SO: Schizophrenia genetics at the millennium: cautious optimism. 
Clin Genet 1997; 52:404–407. 
89. Gottesman II, Shields J: Schizophrenia and Genetics: A Twin Study Vantage Point. New 
York, Academic Press, 1972. 
90. Gottesman II, Shields J: Genetic theorizing and schizophrenia. Br J Psychiatry 1973; 
122:15–30. 
91. Grandgeorge M, Hausberger M, Tordjman S, Deleau M, Lazartigues A, Lemonnier E. 
Environmental factors influence language development in children with autism 
spectrum disorders. PLoS One. 2009;4:e4683. 
92. Green J, Charman T, McConachie H, Aldred C, Slonims V, Howlin P, et al. Parent-
mediated communication-focused treatment in children with autism (PACT): a 
randomised controlled trial. Lancet. 2010;375(9732):2152-60. 
 111 
93. Griffiths R. (1984), The abilities of young children, High Wycombe, UK, The Test Agency 
Ltd. 
94. Gupta S, Aggarwal S, Rashanravan B, Lee T. Th1- and Th2-like cytokines in CD4+ and 
CD8+ T cells in autism. J Neuroimmunol. 1998;85:106-109. 
95. Hallmayer J, Cleveland S, Torres A, Phillips J, Cohen B, Torigoe T, et al. Genetic 
heritability and shared environmental factors among twin pairs with autism. Arch Gen 
Psychiatry 2011;68:1095–102. 
96. Holmes E, Li JV, Athanasiou T, Ashrafian H, Nicholson JK. Understanding the role of gut 
microbiome-host metabolic signal disruption in health and disease. Trends Microbiol 
2011;19:349–59. 
97. Hopkins MJ, Sharp R, Macfarlane GT. (2002). Variation in human intestinal microbiota 
with age. Dig Liver Dis, 34, S2: 12-18. 
98. Howard, J.S., Sparkman, C.R., Cohen, H.G., Green, G. & Stanislaw, H. (2005) ‘A 
Comparison of Intensive Behavior Analytic and Eclectic Treatments for Young Children 
with Autism’, Research in Developmental Disabilities 26(4): 359–383. 
99. Jamain S, et al. Mutations of the X-linked genes encoding neuroligins NLGN3 and 
NLGN4 are associated with autism. Nature Genet 2003;34:27–29. 
100. Jonsdottir, S. L., Saemundsen, E., Asmundsdottir, G., Hjartardottir, S., Asgeirsdottir, B. 
B., Smaradottir, H. H., et al. (2007). Follow-up of children diagnosed with pervasive 
developmental disorders: Stability and change during the preschool years. Journal of 
Autism and Developmental Disorders, 37(7), 1361–1374. 
101. Jorde LB, et al. Complex segregation analysis of autism. Am. J. Hum. Genet 
1991;49:932–938. 
102. Jyonouchi H, Geng L, Streck DL, Toruner GA. Children with autism spectrum disorders 
(ASD) who exhibit chronic gastrointestinal (GI) symptoms and marked fluctuation of 
 112 
behavioral symptoms exhibit distinct innate immune abnormalities and transcriptional 
profiles of peripheral blood (PB) monocytes. J Neuroimmunol 2011;238:73–80. 
103. Kandel ER: A new intellectual framework for psychiatry. Am J Psychiatry 1998; 
155:457–469. 
104. Kanner L (1943), Autistic disturbances of affective contact. Nervous Child, 250(2), 
217–250. 
105. Kawakami K, Kojima K, Makino I, Kato I, Onoue M. Fasting enhances p-cresol 
production in the rat intestinal tract. Exp Anim 2007;56:301–7. 
106. Kawakami K, Makino I, Asahara T, Kato I, Onoue M. Dietary galacto-oligosaccharides 
mixture can suppress serum phenol and p-cresol levels in rats fed tyrosine diet. J Nutr 
Sci Vitaminol (Tokyo) 2005;51:182–6. 
107. Kawakami K, Makino I, Kato I, Uchida K, Onoue M. p-Cresol inhibits IL-12 production 
by murine macrophages stimulated with bacterial immunostimulant. 
Immunopharmacol Immunotoxicol 2009;31:304–9. 
108. Kim SH, Lord C (2012), Combining information from multiple sources for the 
diagnosis of autism spectrum disorders for toddlers and young preschoolers from 12 
to 47 months of age. Journal of Child Psychology and Psychiatry, 53(2), 143– 151. 
109. King M, Bearman P. Diagnostic change and the increased prevalence of autism. Int J 
Epidemiol. 2009;38:1224-1234. 
110. King R.A., May B.L., Davies D.A., Bird A.R. (2009), Measurement of phenol and p-cresol 
in urine and feces using vacuum microdistillation and high-performance liquid 
chromatography. Analytical Biochemistry 384, 27-33. 
111. Kinross JM, Darzi AW, Nicholson JK. Gut microbiome–host interactions in health and 
disease. Genome Med 2011;3:14. 
112. Kitagawa A. Effects of cresols (O-, M-, and P-isomers) on the bioenergetic system in 
 113 
isolated rat liver mitochondria. Drug Chem Toxicol 2001;24:39–47. 
113. Kleinman JM, Ventola PE, Pandey J, Verbalis AD, Barton M, Hodgson S, Green J, 
Dumont-Mathieu T, Robins DL, Fein D. 2008. Diagnostic stability in very young 
children with autism spectrum disorders. J Autism Dev Disord 38:606–615. 
114. Klin A, Saulnier CA, Sparrow SS, Cicchetti DV, Volkmar FR, Lord C (2007), Social and 
communication abilities and disabilities in higher functioning individuals with autism 
spectrum disorders: The Vineland and the ADOS. Journal of Autism and Developmental 
Disorders, 37(4), 748–759. 
115. Kraemer HC (2008), DSM Categories and dimensions in clinical and research 
contexts. In JE Helzer, HC Kraemer, RF Krueger, HU Wittchen, PJ Sirovatka, DA Regier 
(a cura di), Dimensional approaches in diagnostic classification. Arlington: American 
Psychiatric Association. 
116. Krauthammer M, Kaufmann CA, Gilliam TC, Rzhetsky A. Molecular triangulation: 
bridging linkage and molecular-network information for identifying candidate genes in 
Alzheimer's disease. Proc. Natl Acad. Sci. USA 2004;101:15148–15153. 
117. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, 
Doyle M, FitzHugh W, Funke R, Gage D, et al: Initial sequencing and analysis of the 
human genome. Nature 2001; 409:860–921. 
118. Larsson HJ, Eaton WW, Madsen KM, et al. Risk factors for autism: perinatal factors, 
parental psychiatric history, and socioeconomic status. Am J Epidemiol. 2005;161:916-
25; discussion 926-928. 
119. Leblond CS, Heinrich J, Delorme R, Proepper C, Betancur C, Huguet G, et al. Genetic 
and functional analyses of SHANK2 mutations suggest a multiple hit model of autism 
spectrum disorders. PLoS Genet. 2012 Feb;8(2):e1002521. Liabeuf S, Barreto DV, 
Barreto FC, Meert N, Glorieux G, Schepers E, Temmar M, Choukroun G, Vanholder R, 
 114 
Massy ZA; European Uraemic Toxin Work Group (EUTox). Free p-cresylsulphate is a 
predictor of mortality in patients at different stages of chronic kidney disease. Nephrol 
Dial Transplant 2010;25:1183–91. 
120. Leboyer M, Bellivier F, Nosten-Bertrand M, Jouvent R, Pauls D, Mallet J: Psychiatric 
genetics: search for phenotypes. Trends Neurosci 1998; 21:102–105. 
121. Lewis DA: In pursuit of the pathogenesis and pathophysiology of schizophrenia: 
where do we stand? (editorial). Am J Psychiatry 2002; 159:1467–1469. 
122. Lin CH, Yang JY. Chemical burn with cresol intoxication and multiple organ failure. 
Burns 1992;18:162–6. 
123. Lord C. Follow-up of two-year-olds referred for possible autism. J Child Psychol 
Psychiatry. 1995;36(8):1365-82. 
124. Lord C, Jones RM (2012), Annual Research Review: Re-thinking the classification of 
autism spectrum disorders. Journal of Child Psychology and Psychiatry, 53(5), 490–509. 
125. Lord C, Petkova E, Hus V, Gan W, Lu F, Martin DM, Ousley O, Guy L, Bernier R, Gerdts J, 
Algermissen M, Whitaker A, Sutcliffe JS, Warren Z, Klin A, Saulnier C, Hanson E, 
Hundley R, Piggot J, Fombonne E, Steiman M, Miles J, Kanne SM, Goin-Kochel RP, Peters 
SU, Cook EH, Guter S, Tiernagel J, Green-Snyder LA, Bishop S, Esler A, Gotham K, 
Luyster R, Miller F, Olson J, Richler J, Risi S (2012b), A Multisite Study of the Clinical 
Diagnosis of Different Autism Spectrum Disorders. Archives of General Psychiatry, 
69(3), 306–313. 
126. Lord C., Risi S., DiLavore P., Shulman C., Thurm A., Pickles A. (2006), Autism from 2 to 
9 years of age, Archives of General Psychiatry, 63: 694-701.  
127. Lord C., Risi S., Lambrecht L., Cook E.H., Leventhal B.L., DiLavore P.C., Pickles A., 
Rutter M. (2000). The Autism Diagnostic Observation Schedule- Generic: A Standard 
measure of social and communication deficits associated with the spectrum of autism,  
 115 
Journal of Autism and Developmental Disorders, 30: 205-223.  
128. Lord C, Rutter M, Le Couteur A (1999), Autism diagnostic observation schedule (ADOS), 
manual. Los Angeles: Western Psychological Services. 
129. Ma D, Salyakina D, Jaworski JM, Konidari I, Whitehead PL, Andersen AN, et al. (2009). 
A genome-wide association study of autism reveals a common novel risk locus at 
5p14.1. Ann Hum Genet, 73; 263-273.  
130. Mahoney, W., Szatmari, P., Maclean, J. E., Bryson, S. E., Bartolucci, G., Walter, S. D., et al. 
(1998). Reliability and accuracy of differentiating between pervasive developmental 
disorder subtypes. Journal of the American Academy of Child and Adolescent 
Psychiatry, 37(3), 278–285. 
131. Mandel HG. Pathways of drug biotransformation: biochemical conjugations. In: LaDu 
BN, Mandel HG, Way EL, editors. Pathways of drug biotransformation. Baltimore: 
Williams and Wilkins; 1971. p. 149–86. 
132. Marshall CR, et al. Structural variation of chromosomes in autism spectrum disorder. 
Am. J. Hum. Genet 2008;82:477–488.  
133. Mattila ML, Kielinen M, Linna SL, Jussila K, Ebeling H, Bloigu R, Joseph RM, Moilanen I 
(2011), Autism spectrum disorders according to DSM-IV-TR and comparison with 
DSM-5 draft criteria: an epidemiological study. Journal of the American Academy of 
Child and Adolescent Psychiatry, 50(6):583-592. 
134. Mc Govern C.W., Sigman M. (2005), Continuity and change from early childhood to 
adolescence in autism, Journal of Child Psychology and Psychiatry, 46,4: 401-408. 
135. McPartland JC, Reichow B, Volkmar FR (2012), Sensitivity and specificity of proposed 
DSM-5 diagnostic criteria for autism spectrum disorder. Journal of the American 
Academy of Child and Adolescent Psychiatry, 51(4):368-83. Epub 2012 Mar 14. 
136. Meijers BK, Bammens B, De Moor B, Verbeke K, Vanrenterghem Y, Evenepoel P. Free 
 116 
p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int 
2008;73:1174–80. 
137. Meijers BK, Van Kerckhoven S, Verbeke K, Dehaen W, Vanrenterghem Y, Hoylaerts 
MF, et al. The uremic retention solute p-cresyl sulfate and markers of endothelial 
damage. Am J Kidney Dis 2009;54:891–901. 
138. Meyer G, Varoqueaux F, Neeb A, Oschlies M, Brose N. The complexity of PDZ domain-
mediated interactions at glutamatergic synapses: a case study on neuroligin. 
Neuropharmacology 2004;47:724–733. 
139. Miller JN, Ozonoff S (2000), The external validity of Asperger disorder: Lack of 
evidence from the domain of neuropsychology. Journal of Abnormal Psychology, 109(2), 
227–238. 
140. Moessner R, et al. Contribution of SHANK3 mutations to autism spectrum disorder. 
Am. J. Hum. Genet 2007;81:1289–1297. 
141. Molloy CA, Keddache M, Martin LJ. Evidence for linkage on 21q and 7q in a subset of 
autism characterized by developmental regression. Mol. Psychiatry 2005;10:741–746. 
142. Moore V, Goodson S. How well does early diagnosis of autism stand the test of time? 
Follow-up study of children assessed for autism at age 2 and development of an early 
diagnostic service. Autism. 2003;7(1):47-63. 
143. Morgan JT, Chana G, Pardo CA, et al. Microglial activation and increased microglial 
density observed in the dorsolateral prefrontal cortex in autism. Biol Psychiatry. 
2010;68:368-376. 
144. Moss, J., Magiati, I., Charman, T., & Howlin, P. (2008). Stability of the Autism diagnostic 
interview-revised from pre-school to elementary school age in children with autism 
spectrum disorders. Journal of Autism and Developmental Disorders, 38, 1081–1091. 
145. Mullen, E.M. (1995). Mullen Scales of Early Learning: AGS Edition. Circle Pines, MN: 
 117 
American Guidance Service. 
146. Nakabayashi I, Nakamura M, Kawakami K, Ohta T, Kato I, Uchida K, et al. Effects of 
symbiotic treatment on serum level of p-cresol in haemodialysis patients: a 
preliminary study. Nephrol Dial Transplant 2011;26:1094–8. 
147. Nishimura Y, et al. Genome-wide expression profiling of lymphoblastoid cell lines 
distinguishes different forms of autism and reveals shared pathways. Hum. Mol. Genet 
2007;16:1682–1698. 
148. OECD. m-/p-Cresol category, screening information data set, initial assessment 
report. Paris: UNEP Publications; 2003. Available at 
www.chem.unep.ch/irptc/sids/oecdsids/m-p-cresols.pdf. 
149. Ozonoff, S. (2013). Editorial: Recovery from autism spectrum disorder (ASD) and the 
science of hope. Journal of Child Psychology and Psychiatry 54:2;  113–114. 
150. Parracho HM, Bingham MO, Gibson GR, McCartney AL. Differences between the gut 
microflora of children with autistic spectrum disorders and that of healthy children. J 
Med Microbiol 2005;54:987–91. 
151. Persico AM. Autisms. In: Comprehensive Developmental Neuroscience, Rakic P and 
Rubenstein J, editors. San Diego: Elsevier; 2013. 
152. Persico AM, Bourgeron T. Searching for ways out of the autism maze: genetic, 
epigenetic and environmental clues. Trends Neurosci 2006;29:349–58. 
153. Persico AM, Napolioni V, Urinary p-cresol in autism spectrum disorder, Neurotoxicol 
Teratol (2012), http://dx.doi.org/10.1016/j.ntt.2012.09.002 
154. Philippi A, Tores F, Carayol J, Rousseau F, Letexier M, Roschmann E, Lindenbaum P, 
Benajjou A, Fontaine K, Vazart C, Gesnouin P, Brooks P, Hager J. (2007). Association of 
autism with polymorphisms in the paired-like homeodomain transcription factor 1 
(PITX1) on chromosome 5q31: a candidate gene analysis. BMC Med Genet. 2007 Dec 
 118 
6;8:74. 
155. Poliak S, et al. Caspr2, a new member of the neurexin superfamily, is localized at the 
juxtaparanodes of myelinated axons and associates with K+ channels. Neuron 
1999;24:1037–1047. 
156. Ramakrishna BS, Roberts-Thomson IC, Pannall PR, Roediger WE. Impaired sulphation 
of phenol by the colonic mucosa in quiescent and active ulcerative colitis. Gut 
1991;32:46–9. 
157. Ramoz N, Reichert JG, Smith CJ, Silverman JM, Bespalova IN, Davis KL, Buxbaum JD. 
(2004). Linkage and association of the mitochondrial aspartate/glutamate carrier 
SLC25A12 gene with autism. Am J Psychiatry. 2004 Apr;161(4):662-9. 
158. Renwick AG, Thakrar A, Lawrie CA, George CF.Microbial amino acidmetabolites and 
bladder cancer: no evidence of promoting activity in man. Hum Toxicol 1988;7:267–72. 
159. Risi S, Lord C, Gotham K, Corsello C, Chrysler C, Szatmari P, Cook EH Jr, Leventhal BL, 
Pickles A (2006), Combining information from multiple sources in the diagnosis of 
autism spectrum disorders. Journal of the American Academy of Child and Adolescent 
Psychiatry, 45(9), 1094– 1103. 
160. Roberts MS, Anderson RA, Swarbrick J. Permeability of human epidermis to the 
phenolic compounds. J Pharm Pharmacol 1977;29:677–89. 
161. Robertson MA, Sigalet DL, Holst JJ, Meddings JB, Wood J, Sharkey KA. Intestinal 
permeability and glucagon-like peptide-2 in children with autism: a controlled pilot 
study. J Autism Dev Disord 2008;38:1066–71. 
162. Rogers S. (2001), Diagnosis of autism before the age of 3, International Review of 
Mental Retardation, 23: 1-31.  
163. Rogers S.J., DiLalla D.L. (1994), Domains of the Childhood Autism Rating Scale: 
relevance for diagnosis and treatment,  Journal of Autism and Developmental Disorders, 
 119 
24: 115-128. 
164. Roid, G. H., & Miller, L. J. (1997). Leiter International Performance Scale-Revised. 
Wood Dale, IL: Stoelting Co. 
165. Ronald A, et al. Genetic heterogeneity between the three components of the autism 
spectrum: a twin study. J. Am. Acad. Child Adolesc. Psychiatry 2006;45:691–699. 
166. Rondeau, E., Klein, L. S., Masse, A., Bodeau, N., Cohen, D., & Guile, J. M. (2011). Is 
pervasive developmental disorder not otherwise specified less stable than autistic 
disorder? A meta-analysis. Journal of Autism and Developmental Disorders . 
167. Schopler, E., Reichler, R.J., & Renner, B.R. (1988). The Childhood Autism Rating Scale. 
Los Angeles: Western Psychological Services. 
168. Scott FJ, Baron-Cohen S, Bolton P, Brayne C (2002), The CAST (Childhood Asperger 
Syndrome Test): Preliminary development of a UK screen for mainstream primary-
schoolage children. Autism, 6(1), 9–31. 
169. Seak CK, Lin CC, Seak CJ, Hsu TY, Chang CC. A case of black urine and dark skin – 
cresol poisoning. Clin Toxicol (Phila) 2010;48:959–60. 
170. Sebat J, et al. Large-scale copy number polymorphism in the human genome. Science 
2004;305:525–528. 
171. Segurado R, Conroy J, Meally E, Fitzgerald M, Gill M, Gallagher L. (2005). Confirmation 
of association between autism and the mitochondrial aspartate/glutamate carrier 
SLC25A12 gene on chromosome 2q31. Am J Psychiatry. 2005 Nov;162(11):2182-4. 
172. Selmer T, Andrei PI. p-Hydroxyphenylacetate decarboxylase from Clostridium 
difficile. A novel glycyl radical enzyme catalysing the formation of p-cresol. Eur J 
Biochem 2001;268:1363–72. 
173. Sharma S, Woolfson LM, Hunter SC (2011), Confusion and inconsistency in diagnosis 
of Asperger syndrome: A review of studies from 1981 to 2010. Autism, 16(5), 465-86.  
 120 
174. Shaw W. Increased urinary excretion of a 3-(3-hydroxy-phenyl)-3-hydroxypropionic 
acid (HPHPA), an abnormal phenylanine metabolite of Clostridia spp. In the 
gastrointestinal tract, in urine samples from patients with autism and schizophrenia. 
Nutr Neurosci 2010;13:135–43. 
175. Singh VK, Warren R, Averett R, Ghaziuddin M. Circulating autoantibodies to neuronal 
and glial filament proteins in autism. Pediatr Neurol. 1997;17:88-90. 
176. Sklar P: Linkage analysis in psychiatric disorders: the emerging picture. Annu Rev 
Genomics Hum Genet 2002; 3:371–413. 
177. Skuse, D., Warrington, R., Bishop, D., Chowdhury, U., Lau, J., Mandy, W., et al. (2004). 
The developmental, dimensional and diagnostic interview (3di): A novel computerized 
assessment for autism spectrum disorders. Journal of the American Academy of Child 
and Adolescent Psychiatry, 43(5), 548–558. 
178. Song Y, Liu C, Finegold SM. Real-time PCR quantitation of clostridia in feces of autistic 
children. Appl Environ Microbiol 2004;70:6459–65. 
179. Sparrow, S.S., Balla, D.A., Cicchetti, D.V. (1984). Vineland Adaptive Behavior Scales: 
intervention edition, survey form manual. Circle Pines, MN: American Guidance 
Service. 
180. Steffenburg S, et al. A twin study of autism in Denmark, Finland, Iceland, Norway and 
Sweden. J. Child Psychol. Psychiatry 1989;30:405–416. 
181. Stone JL, et al. Evidence for sex-specific risk alleles in autism spectrum disorder. Am. 
J. Hum. Genet 2004;75:1117–1123.  
182. Stone WL, Lee EB, Ashford L, Brissie J, Hepburn SL, Coonrod EE, et al. Can autism be 
diagnosed accurately in children under 3 years? J Child Psychol Psychiatry. 
1999;40(2):219-26. 
 121 
183. St Pourcain B, Wang K, Glessner JT, Golding J, Steer C, Ring SM, Skuse DH, Grant SF, 
Hakonarson H, Davey Smith G. (2010). Association between a high-risk autism locus on 
5p14 and social communication spectrum phenotypes in the general population. Am J 
Psychiatry. 2010 Nov;167(11):1364-72. doi: 10.1176/appi.ajp.2010.09121789. Epub 
2010 Jul 15. 
184. Strauss KA, et al. Recessive symptomatic focal epilepsy and mutant contactin-
associated protein-like 2. N. Engl. J. Med 2006;354:1370–1377. 
185. Szatmari, P. (2000). The classification of autism, Asperger’s syndrome, and pervasive 
developmental disorder. Revue Canadienne de Psychiatrie, 45(8), 731–738. 
186. Szatmari, P. (2011). New recommendations on autism spectrum disorder. Shifting the 
focus from subtypes to dimensions carries potential costs and benefits. BMJ, 342, 
d2456doi:10.1136/bmj.d2456. 
187. Thompson DC, Perera K, London R. Studies on the mechanism of hepatotoxicity of 4-
methylphenol (p-cresol): effects of deuterium labeling and ring substitution. Chem Biol 
Interact 1996;101:1-11. 
188. Trottier, G., Srivastava, L. Walker, C.D. 1999. Etiology of infantile autism: a review of 
recent advances in genetic and neurobiological research. J. Psychiatry Neurosci., 
24:103. 
189. Turner L.M, Stone W.L. (2007), Variability in outcome for children with an ASD 
diagnosis at age 2, Journal of Child Psychology and Psychiatry, 48, 8: 793-802.  
190. Turner LM, Stone WL, Pozdol SL, Coonrod EE. Follow-up of children with autism 
spectrum disorders from age 2 to age 9. Autism. 2006;10(3):243-65. 
191. Vanholder R, De Smet R, Waterloos MA, Van Landschoot N, Vogeleere P, Hoste E, et al. 
Mechanisms of uremic inhibition of phagocyte reactive species production: 
characterization of the role of p-cresol. Kidney Int 1995;47:510–7. 
 122 
192. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial 
activation and neuroinflammation in the brain of patients with autism. Ann Neurol. 
2005;57:67-81. 
193. Veenstra-VanderWeele J, Blakely RD. Networking in autism: leveraging genetic, 
biomarker and model system findings in the search for new treatments. 
Neuropsychopharmacology 2012;37:196–212. 
194. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO, Yandell M, 
Evans CA, Holt RA, Gocayne JD, Amanatides P, et al: The sequence of the human 
genome. Science 2001; 291:1304–1305; correction, 2001; 292:1838. 
195. Ventola P, Kleinman J, Pandey J, Wilson L, Esser E, Boorstein H, Dumont- Mathieu T, 
Marshia G, Barton M, Hodgson S, et al. 2007. Differentiating between autism spectrum 
disorders and other developmental disabilities in children who failed a screening 
instrument for ASD. J Autis Dev Disord 37:425–436. 
196. Voineagu I, Wang X, Johnston P, et al. Transcriptomic analysis of autistic brain reveals 
convergent molecular pathology. Nature. 2011;474:380- 384. 
197. Vorstman JA, et al. Identification of novel autism candidate regions through analysis 
of reported cytogenetic abnormalities associated with autism. Mol. Psychiatry 
2006;11:18–28. 
198. Walker, D. R., Thompson, A., Zwaigenbaum, L., Goldberg, J., Bryson, S. E., Mahoney, W. 
J., et al. (2004). Specifying PDD-NOS: A comparison of PDD-NOS, Asperger syndrome, 
and autism. Journal of the American Academy of Child and Adolescent Psychiatry, 
43(2), 172–180. 
199. Walsh P, Elsabbagh M, Bolton P, Singh I. In search of biomarkers for autism: scientific, 
social and ethical challenges. Nat Rev Neurosci 2011;12:603–12. 
200. Wang L, Angley MT, Gerber JP, Sorich MJ. A review of candidate urinary biomarkers 
 123 
for autism spectrum disorder. Biomarkers 2011a;16:537–52. 
201. Wang L, Christophersen CT, Sorich MJ, Gerber JP, Angley MT, Conlon MA. Low relative 
abundances of the mucolytic bacterium Akkermansia muciniphila and Bifidobacterium 
spp. in Feces of Children with Autism. Appl Environ Microbiol 2011b;77:6718–21. 
202. Wang K, Zhang H, Ma D, Bucan M, Glessner JT, Abrahams BS, et al. (2009). Common 
genetic variance on 5p14.1 associate with autism spectrum disorders. Nature, 459; 
528-533. 
203. Wechsler D. (1990), Wechsler Preschool and Primary Scale of Intelligence—revised, 
Amersham, UK, The Psychological Corporation. 
204. Weiss LA, Arking DE, Daly MJ, Chakravarti A (2009). A genome-wide linkage and 
association scan reveals novel loci for autism. Nature, 461; 802-808. 
205. Whited GM, Gibson DT. Toluene-4-monoxygenase, a three component enzyme system 
that catalyzes the oxidation of toluene to p-cresol in Pseudomonas mendocina KR1. J 
Bacteriol 1991;173:3017–20. 
206. Williams BL, Hornig M, Buie T, Bauman ML, Paik MC, Wick I, et al. Impaired 
carbohydrate digestion and transport and mucosal dysbiosis in the intestines of 
children 
with autism and gastrointestinal disturbances. PLoS One 2011;6:e24585. 
207. Wing L, Gould J (1978), Systematic recording of behaviours and skills of retarded and 
psychotic children. Journal of Autism and Childhood Schizophrenia, 8(1), 79–97. 
208. Wing, L., Leekam, S. R., Libby, S. J., Gould, J., & Larcombe, M. (2002). The diagnostic 
interview for social and communication disorders: Background, inter-rater reliability 
and clinical use. Journal of Child Psychology and Psychiatry, 43(3), 307–325. 
209. Woolfenden S, Sarkozy V, Ridley G, Williams K (2012). A systematic review of the 
diagnostic stability of Autism Spectrum Disorder. Research in Autism Spectrum 
 124 
Disorders 6; 345–354. 
210. World Health Organization (1992), The ICD-10 Classification of Mental and Behavioral 
Disorders: Clinical Descriptions and Diagnostic Guidelines, World Health Organization, 
Geneva, Switzerland. 
211. World Health Organization (WHO). (1993). The ICD-9 classification of mental and 
behavioural disorders. Geneva, Switzerland: Diagnostic criteria for research. 
212. World Health Organization (WHO). (2007). The ICD-10 classification of mental and 
behavioural disorders. Geneva, Switzerland: Diagnostic criteria for research. 
213. Wu ML, Tsai WJ, Yang CC, Deng JF. Concentrated cresol intoxication. Vet Hum Toxicol 
1998;40:341–3. 
214. Yan Z, Zhong HM, Maher N, Torres R, Leo GC, Caldwell GW, et al. Bioactivation of 4-
methylphenol (p-cresol) via cytochrome P450-mediated aromatic oxidation in human 
liver microsomes. Drug Metab Dispos 2005;33:1867–76. 
215. Yap IK, Angley M, Veselkov KA, Holmes E, Lindon JC, Nicholson JK. Urinary metabolic 
phenotyping differentiates children with autism from their unaffected siblings and age-
matched controls. J Proteome Res 2010;9:2996–3004. 
216. Yehuda S, Carasso RL, Mostofsky DI. Essential fatty acid preparation (SR-3) raises the 
seizure threshold in rats. Eur J Pharmacol 1994;254:193–8. 
217. Yokoyama MT, Carlson JR. Production of skatole and p-cresol by a Rumen 
Lactobacillus sp. Appl Environ Microbiol 1981;41:71–6. 
218. Yokoyama MT, Tabori C, Miller ER, Hogberg MG. The effects of antibiotics in the 
weanling pig diet on growth and the excretion of volatile phenolic and aromatic 
bacterial metabolites. Am J Clin Nutr 1982;35:1417–24. 
219. Zoghbi HY. Postnatal neurodevelopmental disorders: meeting at the synapse? Science 
2003;302:826–830. 
